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Abstract 
Tuberculosis, which is caused by the pathogenic bacterium Mycobacteria 
tuberculosis (MTB), is an infectious disease that remains a significant 
worldwide health threat. Galactofuranose (Galf) residues play an 
imperative role in the growth of MTB as it is an essential component in 
the cell wall of this bacterium. UDP-Galactopyranose mutase (UGM) is a 
flavoenzyme that involved in Galf biosynthesis. It catalyzes the reversible 
conversion of UDP-galactopyranose (UDP-Galp) to UDP-galactofuranose 
(UDP-Galf).  
The absence of both UGM and Galf residues in humans make UGM a 
target for new TB therapeutic drugs. This has also brought us to an 
interest in UGM. 
Fourteen potential inhibitors of UGM were identified by alternating the R 
groups of the structure found computationally (Figure 1), and 
successfully synthesised in this project. Besides, HPLC assay was carried 
out to determine the purity of these inhibitors. Subsequently, docking 
experiments were performed to dock these compounds into the X-ray 
structure of Deinococcus radiodurans UGM. Further insight of the docking 
result is evaluated. 
 
Figure 1 General structure of the potential inhibitors of UGM identified. R’ and 
R’’ are different substituents. 
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Abbreviations 
Ac Acetyl 
AFB Acid-fast Gram-positive bacterium 
BCG  Bacillus Calmette-Guerin 
Boc  N-tert-Butoxycarbonyl 
CD4+ Cluster of differentiation 4 
CD8+ Cluster of differentiation 8 
d  Doublet 
dd  Doublet of doublets 
DCM  Dichloromethane 
DIPEA  N,N-Diisopropylethylamine 
DMF  Dimethylformamide 
DMSO  Dimethyl sulphoxide 
dq  Doublet of quartets 
drUGM  Deinococcus radiodurans UGM 
drUGMox  Oxidised drUGM 
drUGMred  reduced drUGM 
ecUGM  Escherichia coli UGM 
EEA1  Early endosomal autoantigen 1 
ESI  Electro spray ionisation 
ESI-MS  Electro spray ionisation mass spectroscopy 
Et  Ethyl  
FAD  Flavin adenine dinucleotide (oxidized form) 
FADH2/FADred Flavin adenine dinucleotide (reduced form) 
FADH•  FADH semiquinone 
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h  Hour 
IR  Infrared spectroscopy 
HBTU  O-Benzotriazole-N,N,N',N'-tetramethyl-uronium-
hexafluoro-phosphate 
HMDO  Hexamethyldisiloxane 
HPLC  High performance liquid chromatography 
IC50  Half maximal inhibitory concentration 
IR  Infrared spectroscopy 
Kd Dissociation constant 
kpUGM  Klebsiella pneumoniae UGM 
LFERs  Linear free energy relationships 
LR  Lawesson’s reagent 
m  Multiplet 
M  Molar 
MDR  Multi-drug resistant  
Me  Methyl 
Mol  Mole 
Mp  Melting point 
MS  Mass spectroscopy 
MTB  Mycobacterium tuberculosis 
mtUGM  Mycobacteria tuberculosis UGM 
NTM  Nontuberculous mycobacteria 
NMR  Nuclear magnetic resonance 
PIX  Positional isotope exchange 
RNIs  Reactive nitrogen intermediates 
RT  Room temperature 
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s  Singlet (NMR) 
SET  Single electron transfer 
SN1  Nucleophilic substitution monomolecular 
SN2  Nucleophilic substitution bimolecular 
TB  Tuberculosis 
tBu  Tertiary Butyl 
td  Triplet of dublets 
Tert  Tertiary 
TFA  Trifluoroacetic acid 
TLC  Thin layer chromatography 
tt  Triplet of triplets 
UDP  Uridine 5’-diphosphate 
UDP-Galp  UDP-galactopyranose 
UDP-Galf  UDP-galactofuranose 
UGM  Uridine 5’-diphosphate galactopyranose mutase 
WHO  World Health Organisation 
XDR  Extensively drug-resistant 
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1 Introduction 
1.1 Tuberculosis 
Tuberculosis (TB) is an infection caused by Mycobacterium tuberculosis, 
which primarily affects the lungs.2 It is spread by inhaling tiny droplets 
released by infected person when they cough or sneeze. TB is the most 
extensive cause of death in the World today, especially in less 
economically developed countries. The World Health Organisation (WHO) 
reported that there were almost 9 million new cases of TB in 2011 and 
1.4 million of TB deaths (Figure 2).3  
 
Figure 2 Estimated TB incidence rate in 2011.3, 4 
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1.1.1 Symptoms 
TB generally takes months or even years from the time of exposure until 
the symptoms develop. These differ depending on which part of the body 
is affected. In certain cases, the body is infected but no symptom 
develops. This is known as latent TB. On the other hand, if the bacteria 
cause symptoms, it is called active TB. There are two types of TB 
infection, which are pulmonary tuberculosis and extrapulmonary 
tuberculosis.5  
Pulmonary TB is the infection on lungs. The symptoms include lack of 
appetite, weight loss, persistent cough (with phlegm that may be bloody) 
of more than three weeks, breathlessness, high body temperature of 38 
°C, night sweats, tiredness, and inexplicable pain for weeks.6 In the case 
of extrapulmonary tuberculosis, this occurs outside the lungs. It is 
common in people who have weaker immune systems, predominantly 
people with a HIV infection. People with latent TB are more likely to 
develop extrapulmonary TB. The symptoms depend on the part of the 
body which is affected. TB of the lymph node has the symptoms of 
persistent painless inflammation of the lymph nodes. The swollen nodes 
can release fluid over a period of time;7 Skeletal TB will cause painful 
bones, loss of movement in the affected bone or joint and the affected 
bone may fracture easily; Gastrointestinal TB will cause abdominal pain, 
diarrhoea, and rectal bleeding; Central nervous system TB will cause 
headache, stiff neck, blurred vision, and unstable mental state.8 
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1.1.2 Causes 
The main cause of TB is a small aerobic non-motile bacillus, 
Mycobacterium tuberculosis (MTB). It is spread in a similar way as the 
common cold or flu. However, it is not as contagious as the infection will 
only occur when one spends prolonged periods in close contact with an 
infected person. Moreover, not everyone with TB is infectious. In general, 
people with extrapulmonary TB do not spread the infection.5 
Other TB-causing MTB complexes include Mycobacterium bovis, 
Mycobacterium africanum, Mycobacterium microti and Mycobacterium 
canetti.  Mycobacterium bovis used to be a common cause of TB until the 
introduction of pasteurised milk, which has largely reduced this as a 
public health problem in developed countries.9 Mycobacterium africanum 
is not widespread except in certain parts of Africa.10 Mycobacterium 
microti is mostly found in immunodeficient people.11 A few cases that 
involve Mycobacterium canetti have only been seen in African 
emigrants.12  
Furthermore, the other known pathogenic mycobacteria include 
Mycobacterium leprae and Mycobacterium marinum. Mycobacterium 
kansasii and Mycobacterium avium are part of the nontuberculous 
mycobacteria (NTM) group. NTM cause neither TB nor leprosy. However, 
they cause pulmonary diseases similar to TB, such as skin disease or 
lymphadenitis.5, 13 
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1.1.3 Transmission (mechanism) 
The transmission of TB starts when people with active pulmonary TB 
sneeze, cough, speak or spit.4 These actions release infectious droplets 
that are 0.5 to 5.0 µm in diameter. A sneeze can produce up to 40,000 
droplets and each of these may transmit the disease as the infectious 
dose of bacteria is very low (<10 bacteria may cause an infection).14, 15  
Infection rate increases when one has close, long, or frequent contact 
with people infected with TB. Only people with active TB will transmit the 
disease. There are several factors that affect the probability of 
transmission. For instance, the duration of exposure, the number of 
infectious droplets expelled by the carrier, the level of immunity in the 
uninfected person, the effectiveness of ventilation, the virulence of 
the MTB strain, and others.16 Transmission of TB can also occur when one 
ingests TB infected meat. For instance, Mycobacterium bovis causes TB in 
cattle.5 
The chain of transmission can be circumvented through isolation of 
patients with active disease and treatment with effective anti-
tuberculosis regimens.17  
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1.1.4 Diagnosis 
A complete medical evaluation for TB must include medical history, a 
physical examination, a chest X-ray and microbiological examination. It 
may also include a tuberculin skin test, other scans and X-ray, surgical 
biopsy.18 
The common method to diagnose TB worldwide is sputum smear 
microscopy, which was developed more than 100 years ago. Bacteria are 
observed in sputum samples examined under a microscope. Recently, the 
use of rapid molecular tests for the diagnosis of TB and drug resistant TB 
is increasing. Besides, TB is diagnosed using a culturing method in those 
countries with more developed laboratory capacity.4, 19  
It is difficult to diagnose active tuberculosis based only on signs and 
symptoms as some patients are immunosuppressed and may have these 
symptoms for other reasons.18 
1.1.5 Prevention, treatment and resistance 
Bacillus Calmette-Guerin (BCG) was the first vaccine for TB that was 
developed in France between 1905 and 1921.20 This vaccine is widely use 
as part of the TB control programme in many countries, especially for 
infants. For countries where TB is uncommon, BCG is only administered 
to people at high risk. BCG has a protective efficacy of greater than 80% 
towards preventing serious forms of TB in children.21 As for preventing 
pulmonary TB in adolescents and adults, its protective efficacy ranges 
from 0 to 80%.5 
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For people diagnosed with TB, an appropriate treatment should be given. 
Generally, a conventional short-course therapy will be given. The most 
effective combination is isoniazide, rifampicin, ethambutol, and 
pyrazinamide for two months, followed by isoniazide and rifampicin for 4 
months.1 This therapy is also effective for patients with HIV infection.4 A 
single antibiotic is usually used for latent TB treatment, while a 
combination of several antibiotics are used for active TB.5  
The first line TB drugs are used initially to treat TB, and second line TB 
drugs are used when resistance to first line therapy, multi-drug resistant 
tuberculosis (MDR-TB) or extensively drug-resistant (XDR) tuberculosis 
occur. The first line TB drugs and second line TB drugs are listed in 
Figure 3, together with the structures (Figure 4).  
 
 
 
 
 
 
 
 
 
 
Most                   
Effective                  Least 
                 tolerable 
  Injectable drugs Oral bacteriostatics 
Rifampicin 
Isoniazide 
Pyrazinamide 
Ethambutol 
Fluoroquinolones 
   moxifloxacin 
   gatifloxacin 
   levofloxacin 
Aminoglycosides 
   streptomycin 
   amikacin 
   kanamycin 
Polypeptides 
   capreomycin 
ethionamide, 
protionamide 
cycloserine, terizidone, 
p-aminosalicyclic acid, 
thioacetzone 
 1
s t line 
 drugs 
2nd line drugs 
Figure 3 Current prescribed antituberculars. The first-line drugs and various classes of 
second-line drugs in descending order of tolerability and potency.1 
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Figure 4 Structures of the first line and second line TB drugs. 
Drug resistant TB is spread in a similar way as regular TB. Primary 
resistance occurs when a person is infected with a resistant strain of TB. 
Secondary resistance develops during TB therapy when the patient is 
given an inadequate treatment.22 MDR-TB is defined as resistance to the 
two most effective first-line TB drugs, which are rifampicin and 
isoniazid.19 XDR-TB is resistant to at least rifampicin and isoniazid, plus 
to any quinoline and at least one injectable second-line agent (see Figure 
3).4  
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1.2 Mycobacterium tuberculosis 
1.2.1 General Characteristics 
Mycobacterium tuberculosis (Error! Reference source not found. (a)) 
as first discovered by the German physician and scientist, Robert Koch on 
March 24, 1882.5 It is the causative agent of tuberculosis and infects 
primarily mammalian respiratory system (e.g. lungs). MTB is an aerobic, 
nonmotile bacillus that is classified as a Gram positive bacterium due to 
the presence of cell wall and lacks of phospholipid outer membrane.23 It 
either stains very weakly Gram-positive or is impervious to any 
bacteriological stain due to high lipid and mycolic acid content in its cell 
wall.23 
Since MTB does not seem to fit the Gram-positive category from the 
empirical point of view (i.e. they generally do not retain the crystal violet 
stain well), it is classified as an acid-fast Gram-positive bacterium (AFB) 
as it retains certain stains after being treated with acidic solution.7 The 
acid-fast staining technique, called Ziehl-Neelsen staining, dyes AFBs a 
bright red that stands out clearly against blue background (Error! 
eference source not found.(b)). An auramine-rhodamine stain and 
fluorescent microscopy are other ways to visualize AFBs.5 MTB requires 
high levels of oxygen to grow.23  
MTB divides with an exceptionally slow rate compared with other bacteria 
(E. coli divides every 20-30 minutes), which is every 16 to 20 hours.5 
The unusual cell wall of MTB enables it to endure mild disinfectants and 
survive in a dry state for weeks.24  
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(a)                                                          (b) 
          
 
 
 
Figure 5 (a) Colonies of Mycobacterium tuberculosis growth on a culture plate.5 (b) 
Microscope image of red-stained TB bacteria.5 
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1.2.2 Cell wall structure 
The bacteria are classified in the genus Mycobacterium based on the fact 
of their acid-fastness, a high (60-70 mol %) guanine plus cytosine (G+C) 
content in their deoxyribonucleic acid (DNA), and the presence of mycolic 
acid (Figure 6) containing 70-90 carbons. There are other species of 
acid-fast bacteria (i.e. Norcadia, Tsukamurella, Rhodococcus, Gordonia), 
but they stain less intensely due to their shorter mycolic acids chains.24  
 
 
Figure 6 Cell wall of MTB showing key role of UDP-Galf and molecular structure 
of mycolic acids.25 
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The cell wall of MTB is hydrophobic, waxy and rich in mycolic acids, which 
makes it a key virulence factor. The inner layer is composed of 
peptidoglycan which is covalently linked to an arabinogalactan layer. The 
outer membrane contains mycolic acids, (mannose-capped) lipomannan, 
and mannoglycoproteins.  
 
Figure 7 A schematic representations of the major components of the 
Mycobacteria cell wall and their distributions.  
1.2.3 Strain variation 
MTB is a pathogenic bacteria species in the genus Mycobacterium, within 
the order Actinomycetales that comprises a number of well characterised 
species. The most common species are MTB and Mycobacterium leprae 
(Leprosy). The genetic variation of MTB results in significant phenotypic 
differences between clinical isolates. Different strains of MTB are 
connected with different geographic regions. Nevertheless, phenotypic 
studies show that the development of new diagnostics and vaccines has 
22 
 
no relation to the strain variation. Yet, micro-evolutionary variation does 
influence the relative fitness and transmission dynamics of antibiotic-
resistant strains.5, 26 
1.2.4 Pathophysiology 
Normally, when a host is infected with MTB, the immune response will 
increase by eliciting cluster of differentiation 4 (CD4+) and cluster of 
differentiation 8 (CD8+) T cells as well as antibodies specific for 
mycobacterial antigens. It is believed that the bacterial pathogen persists 
in the host even though the immune response is sufficient to stop the 
progression to active disease.27, 28  
The bacterium can survive within macrophage, which are responsible for 
eliminating microbes. Two major antimicrobial mechanisms of 
macrophages are phagolysosome fusion and the production of toxic 
reactive nitrogen intermediates (RNIs). RNIs (e.g. nitric oxide, nitrite, 
and nitrate) are toxic molecules produce by the immune system which 
helps in the destruction of pathogens.29 Infected macrophages can be 
detected by CD4+ T cells.5  
Mechanisms have been developed by MTB in order to avoid detection by 
the host and allow them to persist within macrophages. They can survive 
by modulating antigen presentation to prevent the detection of infected 
macrophages by T cells. Moreover, they can also survive by evading 
macrophage killing mechanisms that is mediated by nitric oxide and 
related RNIs.27  
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MTB is spread through air when people with active MTB infection sneeze, 
cough or spit. A single sneeze can release up to 40,000 droplets.14 A 
droplet nuclei (0.5 to 5.0 µm in diameter) contains no more than 3 
bacilli. It can remain air-borne for long period of time. After droplet 
nuclei are inhaled, they enter the lungs and MTB is taken up by alveolar 
macrophages. However, the bacterium is unable to be digested. The MTB 
cell wall prevents the fusion of the phagosome with a lysosome. MTB 
tends to block the bridging molecule, early endosomal autoantigen 1 
(EEA1). However, the blockade does not prevent fusion of vesicles filled 
with nutrients. Subsequently, the bacteria multiply continuously within 
the macrophage. The UreC gene that is carried by bacteria will prevent 
the acidification of the phagosome.30 Besides, to evade macrophage-
killing mechanisms, the bacteria will develop various mechanisms to 
escape from the toxicity of the RNIs.5, 27 
1.3 Uridine 5’-diphosphate galactopyranose mutase (UGM)   
UGM, a flavoprotein with the flavin adenine dinucleotide (FAD) coenzyme 
bound noncovalently, plays an essential role in galactofuranose 
biosynthesis in microorganisms. It is vital for viability in mycobacteria. 
UGM (Rv3809c) is glf-encoded enzyme31 that catalyzes the reversible 
interconversion of UDP-galactopyranose (UDP-Galp) into UDP-
galactofuranose (UDP-Galf) (Scheme 1).25 UDP-Galf is the activated 
precursor of D-Galactofuranose (Galf) residues, which are the crucial 
component of the arabinogalactan complex found in certain pathogenic 
bacteria such as Klebsiella pneumoniae and Escherichia coli. UGM is 
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shown to be essential for the growth and survival of M. tuberculosis and 
other pathogenic bacteria.3, 32  
 
Scheme 1 The overall reaction catalysed by UGM. The equilibrium favours 
formation of the six-membered pyranose form over the five membered furanose 
form.33 
1.3.1 Crystal structure and binding site of UGM 
The mutase is a mixed / class of protein (the secondary structure is 
composed of -helices and -strands along the backbone, where -
strands are mostly parallel) that exists as a dimer.34 Each monomer 
binds one molecule of FAD. The first crystal structure of UGM (Figure 8) 
from E. coli (ecUGM) was reported by Sanders et al. at a resolution of 2.4 
Å (PDB code: 1I8T).25 The flavin nucleotide was found to be located in a 
cleft lined with conserved residues (H56, Y311, R340, Y346, and D348). 
According to the site-directed mutagenesis studies performed, the cleft 
contains the substrate binding site together with the sugar ring of the 
UDP-galactose neighbouring to the exposed isoalloxazine ring of FAD. 
Sanders et al. concluded that this enzyme was only active when the 
flavin was reduced.25  
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Figure 8 Ribbon diagram of E. coli UGM dimer. Monomer A is coloured blue; and 
monomer B is coloured green; FAD is shown in red. 
More recently, the crystal structures of M. tuberculosis UGM (mtUGM) 
and K. pneumoniae UGM (kpUGM) was reported by Beis et al. at 
resolutions of 2.25 Å and 2.35 Å, respectively.35 The site-directed 
mutagenesis study of kpUGM residues revealed that mutation of the 
conserve arginine (Arg174/ R174) of a mobile loop located away from the 
active site was found to affect the substrate binding and catalytic activity. 
The sequence identity of ecUGM with mtUGM and kpUGM are 42% and 
37%, respectively (Figure 14). Based on Figure 9, the folds of the 
proteins from mtUGM and kpUGM are similar to ecUGM.   
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Figure 9 (a) The dimer structure of the mtUGM. Monomer A coloured in light 
blue; Monomer B coloured in deep blue; and FAD coloured in red. (b) The 
monomer structure of kpUGM is coloured in yellow; and FAD in red.   
(a) 
(b) 
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Partha et al. reported the crystal structure of UGM from Deinococcus 
radiodurans (drUGM) in complex with UDP-Galp (PDB code: 3HDQ).36 The 
crystal structure of drUGM:UDP-Galp complexes with FADred were 
resolved to 2.50 Å resolution. An unusual folded conformation of UDP-
Galp is located in the active site (Figure 10). The anomeric carbon of the 
galactose (UDP-Galp) is at a favourable distance (2.8 Å) from N5 of FAD, 
which is identified to be situated next to the putative substrate binding 
site. 
 
Figure 10 Ribbon diagram of a monomer of drUGMred in complex with UDP-Galp. 
The FAD and UDP-Galp are shown as sticks with the colour of red and green, 
respectively. 
Partha et al. mentioned that reduced drUGM (drUGMred) has a different 
FAD conformation compared to oxidised drUGM (drUGMox). The 
isoalloxazine ring of FAD in drUGMred has butterfly-like bent conformation 
(Figure 11 (a)) with the N5 of FAD nearer to the sugar moiety of 
substrate binding site (Figure 11 (b)).  
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Figure 11 (a) Conformation comparison between FAD of drUGMred (blue) and 
drUGMox (green). (b) Overlay of FAD of drUGMred (blue) and drUGMox (green). 
Note that N5 of fad in drUGMred is closer to the C1 of UDP-Galp compare to 
drUGMox.
36 
Additionally, the electron density of the sugar in drUGMred is clearer 
(Figure 12), which is assumed to stabilize the sugar conformation. 
Moreover, drUGMred has a greater affinity for substrate than oxidized 
drUGM, which explains the possible bond formation between FAD and 
substrate in the mechanism of UGM (Section 1.3.2).36 
 
(a)                                           (b) 
Figure 12 Comparison of the electron density of the sugar between drUGMox (a) 
and drUGMred (b). The density of the sugar moiety in drUGMred is more clearly 
defined compared to drUGMox.
36 
(a) (b) 
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Interestingly, when UDP-Galp binds in the active site of drUGM it adopts 
an unusual fold, which is different compared to the fully extended or fully 
folded substrate conformations observed in the structures of other of 
UDP-Galp utilising enzymes (Figure 13).36, 37 
 
    (a)                       (b)                        (c)           
Figure 13 The conformations of UDP-Galp in drUGMox (a), UDP-
galactosyltransferases (b), and UDP-galactose-4-epimerase (c). 
With the structural information reported in previous research, a multi-
sequence alignment using T_COFFEE38 was carried out to identify 
conserved amino acid residues between different organisms (Figure 14). 
The sequence numbers for conserved key active site residues of UGM 
from K. pneumoniae, E. coli, M. tuberculosis, D. radiodurans, and A. 
fumigatus are given in Table 1. As shown in Table 1, most of the residues 
involved in substrate binding are highly conserved among these UGMs. 
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Figure 14 Sequence alignment of UGMs from D. Radiodurans, E. coli, K. 
pneumonia, and M. Tuberculosis. 25, 36, 39 The sequence identity/similarity is 
based on the alignment of four sequences. The alignment was generated using 
T_COFFEE38 and the graphic is produced by ESPript40. The red boxes denote the 
identical residues between the UGMs. Red characters denote the similarity in a  
group.  
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Table 1 Sequence numbers for conserved active site residues in different species 
of UGM.36, 41, 42 
D. 
radiodurans 
M. 
tuberculosis 
E. coli K. 
pneumoniae 
A. 
fumigatus 
H88 
H109 
F175 
F176 
Y179 
T180 
W184 
R198 
Y209 
F210 
N296 
R305 
E325 
Y335 
R364 
Y370 
N372 
H65 
H89 
F157 
V158 
Y161 
T162 
W166 
R180 
Y191 
F192 
N282 
R292 
E315 
Y328 
R360 
Y366 
D368 
H56 
N80 
L147 
I148 
Y151 
T152 
W156 
K169 
R170 
Y181 
N268 
R278 
E298 
Y311 
R340 
Y346 
D348 
H60 
N84 
F151 
F152 
Y155 
T156 
W160 
R174 
Y185 
F186 
N270 
R280 
E301 
Y314 
R343 
Y349 
D351 
H63 
R91 
F158 
M159 
Y162 
N163 
W167 
R182 
P206 
N207 
Y317 
R327 
E373 
Y419 
R447 
Y453 
N457 
 
1.3.2 Mechanism of UGM 
Several mechanistic studies on UGM have appeared in the literature 
including X-ray crystallographic, kinetic isotope analyses, spectroscopic 
and mutagenesis studies.25, 33, 36, 39, 43-45 Some published literature 
suggest that the reduced enzyme is active and the oxidized enzyme is 
not.33, 44, 46 For example, Sanders et al. showed that the reduction by 
dithionite activates the enzyme whilst oxidation by K3(FeCN6) inactivates 
it.25 Studies also suggested that noncovalently associated FAD plays an 
essential part in catalysis. UGM is catalytically active only when its FAD 
cofactor is in the reduced form.33 The reduced FAD (FADred) was found to 
have different roles, from facilitating transient electron transfer (single 
electron transfer) to serving a structural role within the protein 
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scaffold.44, 47, 48 The X-ray crystallographic analysis of UGM structure 
shows that the enzyme-bound flavin is localized in the putative active 
site.25 It has been observed that the N5 on FAD is important for UGM 
catalytic activity.49 
Previous studies have reported important understandings of the chemical 
mechanism of the UGM-catalyzed reaction. Although several mechanisms 
for UGM have been proposed, a clear insight of the catalytic mechanism 
is still elusive. Besides, the role of FAD cofactor is still puzzling as it can 
exist in different oxidation and ionic states.50 The redox chemistry of this 
coenzyme is normally carried out through transformations involving 
either N5 or C4a of the isoalloxazine ring system.51     
Trejo et al. proposed the first mechanism of the direct transformation of 
UDP-Galp into UDP-Galf (Scheme 2) in 1971.  They suggested that a ring 
contraction occurred while the linkage between the sugar and the 
pyrophosphate remained intact. The mechanism (shown in Scheme 2) 
shows a preferential protonation of the ring oxygen of the pyranose 
nucleotide rather than glycosidic oxygen. This is due to the presence of 
sugar pyrophosphate structure. The pyrophosphate group was expected 
to decrease significantly the basicity of the glycoside oxygen. Therefore, 
preferential protonation of ring oxygen atom is more likely to happen.52  
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Scheme 2 Direct transformation of UDP-Galp into UDP-Galf as proposed by Trejo 
et al.52 
In 1999, Blanchard et al. proposed a hypothetical mechanism (Scheme 
3) based on the results obtained from the 13C NMR and positional isotope 
exchange (PIX) experiments. They reported that the first step involves 
the direct nucleophilic attack of the axial 4’-hydroxyl group on C1, results 
in the breaking of the glycosidic bond, displacing UDP and generating a 
bicycle acetal. The bond between the ring oxygen and C1 is broken (two 
possible pathways, a and b are proposed) in the second step. The last 
step involves the attack of UDP at the anomeric C1 to give UDP-Galf. 44 
Blanchard et al. demonstrated that the phosphate group bound to the 
anomeric position is torsionally unrestricted and statistically scrambled a 
labelled oxygen atom with the same rate as the reaction itself. This 
observation led to the conclusion that during turnover the glycosidic bond 
must be broken as part of the mechanism.47 
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Scheme 3 Hypothetical mechanism for UGM based on PIX data proposed by 
Blanchard et al. in year 1999. U = Uridine; darkened atoms indicate 18O labels.44 
Obviously, the mechanism (Scheme 3) proposed by Blanchard et al. does 
not require any redox transformations involving the enzyme-bound 
flavin, FAD. The role of FAD in this reaction mechanism remains 
obscure.44  
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In 2000, Zhang et al. demonstrated that the catalytic efficiency of UGM 
increased by more than 2 orders of magnitude when UGM is in the 
reduced form. The same result was also observed when FAD was 
selectively reduced by photoreduction in the presence of 5-
deazariboflavin under anaerobic conditions.43  
Early studies suggested that reduction of FAD involves transformation of 
the coenzyme from a highly conjugated planar frame to a “bent butterfly” 
structure, which may provoke a conformational change within the 
enzyme that may become more favourable to catalysis. Furthermore, the 
reduced flavin imparts a more negative character to N1 (Scheme 4), 
which may be used to stabilize the transiently formed oxocarbenium ion 
intermediate (Scheme 3) to facilitate catalysis.43, 46, 53   
 
Scheme 4 FADH- bears a higher electron density at N1.43 
Following on from this, a hypothesized redox mechanism was proposed 
(Scheme 5).54, 55 The mechanism was initiated by the oxidation of 2-OH 
and 3-OH on the galactose moiety (3/ 4). The redox capability of FAD 
was utilized, allowing the oxidation of 2-OH and 3-OH to produce the 
enediols (5/ 6) as possible intermediates. However, this mechanism was 
36 
 
firmly ruled out based on the experiments carried out by Zhang et al. in 
2001.46 Two fluorinated analogues (7/ 8, Figure 15) were tested against 
Escherichia coli mutase. The results obtained show that these two 
compounds act as substrates for the reduced UGM (although 7 was a 
poor substrate). Since the fluorine substituent is redox inert, a 
mechanism initiated by the oxidation of 2-OH and 3-OH on the galactose 
moiety is impossible.46  
 
Scheme 5 A hypothesized mechanism for UGM in which the redox capability of 
FAD is exploited.54, 55 
 
Figure 15 UDP-2F-Galf and UDP-3F-Galf.43 
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In 2003, Fullerton et al. reported that the enzyme is only active when the 
FAD cofactor is in reduced state, and suggesting that a cryptic-redox 
reaction may form part of the mechanism. Thermodynamic analysis of 
the FAD demonstrated that neutral semiquinone (FADH•) is stabilized in 
the presence of substrate. Also, fully reduced flavin is the anionic FADH-, 
not the neutral FADH2. This is because the anionic FADH
- is an ideal 
crypto-redox cofactor as it would allow rapid single electron transfer 
without being slowed by a coupled proton transfer. The thermodynamic 
analysis data obtained has shown that the semiquinone form of FAD is 
thermodynamically accessible under conditions of turnover.47   
A radical-based mechanism (Scheme 6) was suggested by Fullerton et al. 
The mechanism involves a single-electron transfer (SET) to the 
oxocarbenium to generate an anomeric radical. During the UDP-
Galp/UDP-Galf interconversion, the formation of a highly reactive 
anomeric radical would facilitate ring contraction by inducing nucleophilic 
attack by O4 at the C1 position, with the cleavage of the anomeric C1-O5 
bond. The electron would then transferred from the anomeric position 
back to the FAD semiquinone.47  
38 
 
 
Scheme 6 Radical mechanism proposed by Fullerton et al. in 2003. The anomeric 
radical is the key intermediate generated by single electron transfer from FADH- 
to the oxocarbenium ion.47 
Recently, a proposal for the catalytic mechanism of UGM was reported by 
Soltero-Higgin et al. (Scheme 7, path A).33 They concluded that only 
reduced UGM is catalytically active, and the N5 position is only 
nucleophilic when the FAD is in the reduced state. Thus, the FADred is 
being utilized in the catalytic mechanism.  
Soltero-Higgin et al. also established that the lone pair of electrons at the 
N5 position of FADH- is involved in the generation of flavin-derived 
iminium ion 13 (Scheme 7). This putative intermediate 13 was trapped 
by treating UGM with radiolabelled UDP-Galp (C6 is radiolabelled, 
Scheme 7) and sodium cyanoborohydride (NaCNBH3), and a radiolabelled 
flavin-galactose adduct 15 was monitored. This adduct was confirmed to 
be an N5-galactose flavin (15) from the ultraviolet-visible spectroscopy 
and mass spectrometry obtained. The observation of 15 proved that the 
interconversion of the pyranose and furanose form occur via flavin-
derived iminium species 13. 
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According to the mechanism proposed (Scheme 7), these intermediates 
(12 and 14) are formed through the nucleophilic attack by N5 of FADred 
on the anomeric carbon of 1 (or 2) with the concerted cleavage of the 
glycosidic (C1-OUDP) bond, which is a typical SN2-type substitution. 
Alternatively, 12 and 14 can also be generated through SN1-type 
substitution, where elimination of UDP to generate an oxocarbenium 
intermediate 10 precedes the nucleophilic attack by N5 of FADred. 
Nevertheless, the precise protonation state of N1 on each intermediate is 
still imprecise. 33, 56 
Sun et al. summarized three mechanistic hypotheses (Scheme 7) of UGM 
that were published in previous literatures.57 Path A and path B are the 
mechanisms suggested by Soltero-Higgin et al.33 Alternatively, formation 
of 12 and 13 may take place through SET from FADred that is facilitated 
by the electron-deficient nature of 10 (path C). A radical pair (11 and 
16) is formed. 
The investigation carried out by Sun et al. using PIX and linear free 
energy relationships (LFERs) illustrates that SN2-type displacement (path 
A) of UDP from the substrate by N5 of FADred is preferable.
57 The findings 
also prove the nucleophilic participation of FADred during the UGM 
catalysis. Thus, they suggested that future development of UGM 
inhibitors could utilize analogues that specifically target the nucleophilic 
addition.57  
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Scheme 7 Proposed mechanism for the interconversion of UDP-Galp and UDP-
Galf. A radiolabelled substrate (asterisk, radiolabelled position) can serve as a 
mechanistic probe. Species 13 was expected to be reduced by NaCNBH3 to 
produce N5 galactose flavin.57 
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1.3.3 UGM inhibitors reported in literatures  
Several compounds have been designed, synthesised and tested as 
potential inhibitors against different UGM from different bacteria. A few of 
these inhibitors have displayed very good inhibitions toward UGM. They 
include the substituted 2-aminothiazoles, thiazolidinones and pyrazole.58, 
59 Some of the UDP-sugar substrate based,60 nucleotide based,42, 61 and 
non-substrate based33, 62 analogues have been develop as UGM inhibitors 
too. However, only some of these analogues have shown good inhibitory 
activity against UGM.  Following are a few example of the inhibitors found 
in previous studies together with their inhibitory activities (Table 2).    
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Table 2 Examples of compounds with their inhibitory activity.  
Inhibitors Testing References 
 
This indole analogue has 
been tested against UGM 
from different species by a 
HPLC assay. The conversion 
of UDP-Galf to UDP-Galp, in 
the presence and absence of 
inhibitor was monitored. The 
percentage inhibition at 1 mM 
of the inhibitor tested against 
kpUGM was 86%, while the 
half maximal inhibitory 
concentration (IC50) tested 
against kpUGM and mtUGM 
were 1.0 µM. 
Partha et 
al.42 
 
This uridine-based compound 
was examined using a 
microtiter plate assay against 
ecUGM.  IC50 = 6.0 µM. 
However, this compound is 
inactive against  mtUGM. 
Scherman et 
al.61 
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This 2-aminothiazole 
analogue has been tested 
against mtUGM using high-
throughput fluorescence 
polarization (FP) assay.  
Kd = 7.4 µM; % inhibition at 
50 µM of inhibitor = 82%. 
Dykhuizen et 
al.32 
 
FP assay and HPLC assay 
were used to examine this 
inhibitor against kpUGM.  
Kd = 4.0 ± 0.7 µM;  
IC50 = 17 µM. 
Michelle 
Soltero-
Higgin et 
al.56 
 
FP assay was employed to 
test this thiazolidinone 
analogue against kpUGM and 
mtUGM. Kd = 4.3 ± 0.7 µM 
and 6.1 ± 0.5 µM, 
respectively.  
Carlson et 
al.62 
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1.4 Aims 
As discussed earlier, D-Galactofuranose (Galf) residues are vital 
component of the arabinogalactan complex found in the cell walls of 
pathogenic microbes such as MTB, and are crucial for their viability. UGM 
is a unique flavoenzyme that involved in the biosynthesis of Galf. It 
catalyses the reversible conversion of UDP-Galp and UDP-Galf. The latter 
is the activated precursor of Galf residues.  
UGM is targeted for developing novel antibacterial agents due to the 
importance of UGM in mycobacterial growth. Moreover, the absence of 
UGM and Galf residues in humans also make UGM a potential drug target 
for developing new TB therapeutic drugs that are potentially more 
effective and less toxic to human cells.59, 63  
Efforts have been made in designing a number of nucleotide-based, 
sugar-based and non-substrate based compounds to inhibit UGM. 
However, only a few of these have shown inhibitory activity towards 
UGM. Most of these compounds are reversible competitive inhibitors with 
low binding affinities. Both sugar-based and nucleotide compounds 
exhibit poor pharmacokinetics due to their polarity. 42, 56, 61, 62 Thus, there 
is clearly a need to design more drug-like inhibitors of novel therapeutic 
targets such as UGM. 
Previously, the Thomas group identified a few novel inhibitors of UGM by 
structure-based Virtual Screening, which was performed by Dr Ali 
Sadeghi-Khomami.42, 64 It was reported that inhibitors with indole 
analogue 17 (Figure 16) exhibited more than 80% inhibitory activity 
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towards UGM at 1mM and IC50 value of 1.0 µM, when tested against 
kpUGM.42  
 
Figure 16 Inhibitor reported by K. Partha et al.42 
The aim of my project was to synthesize a series of potential inhibitors, 
and then in silico evaluation of these inhibitors would be performed 
against UGMs from different species using GOLD, and if time permitted 
biological evaluation. The crystal structure of drUGM (PDB code: 3HDQ) 
was to be used for the initial docking experiments. Once this has been 
achieved, docking of the inhibitors against other species of UGMs, such 
as kpUGM, mtUGM and ecUGM could then be performed to further 
evaluate binding mode(s) of the inhibitions.  
To determine the potency of these inhibitors, enzyme inhibition assays 
will be carried out by conducting HPLC assay42 and FP assay62 in order to 
determine the percentage inhibition, IC50, and Kd values of these 
inhibitors. HPLC analyses of these inhibitors will be performed to 
determine their purity prior to the enzyme inhibition assays. 
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2 Results & Discussions 
Structure-based virtual screening of the CheMBL65 database was 
performed by Alex Wichlacz.66 Hit compounds identified by this screening 
process are shown to exhibit promising inhibitory activity towards UGM. 
One of the compounds with the best hit, which is 22 has been 
synthesized. The R groups were then alternated with various functional 
groups to produce a series of different analogues (23-35), in order to 
optimize the binding affinity to the active site of UGM.  
In this project, fourteen indole-thiazole based analogues (23-35) have 
been synthesised, each in four steps: protection step; thionation step; 
deprotection, and amide coupling step; Hantzsch Thiazole synthesis. The 
reactions were monitored by thin layer chromatography (TLC) and mass 
spectrometry (MS) to ensure that the starting materials were fully 
consumed. These analogues were successfully purified using 
recrystallisation and flash column chromatography. Characterisation of 
these analogues was performed by utilising MS, NMR, and infrared 
spectroscopy (IR). The synthesis of some additional inhibitor was 
attempted, however due to time limitations, these syntheses were not 
completed.     
HPLC analyses have been carried out to determine the purity of the 
analogues synthesised. At the same time, in silico studies of these 
analogues have been performed to predict their binding positions, 
binding affinities, and interactions against UGM. 
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2.1 Chemical synthesis 
The series of analogues (22-35) were synthesised following the route 
shown in Scheme 8. The route was established previously in the Thomas 
group for the synthesis of indole analogue 17 (Figure 16).  
 
Scheme 8 Synthesis route of the analogues. 
The synthesis was started with the protection of isonipecotamide (18) 
using the di-tert-butoxycarbonyl (BOC) group. The reaction mixture was 
initially a white suspension, and it turned into a colourless solution after 
4 hours of stirring with di-tert-butyl dicarbonate at ambient temperature. 
The physical change in the reaction mixture shows that the reaction was 
proceeding as 18 was found to be insoluble in organic solvents especially 
dichloromethane and chloroform. With the protecting BOC group added, 
this compound dissolved in organic solvents.  Extraction of the reaction 
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solution with 1M HCl and brine was enough to produce a pure 19 as a 
white solid with a good yield of 80%. The product was confirmed by the 
presence of tert-butyl group singlet peak at 1.46 ppm in the 1H NMR 
spectrum (section 4.2.1.1). The reaction mechanism of the BOC 
protecting step is shown in Scheme 9.  
 
Scheme 9 BOC protecting reaction mechanism. 
This amine protection reaction has been achieved with the use of 
catalyst, 4-dimethylaminopyridine (DMAP). However, the yield obtained 
by using DMAP (61%) was lower comparing to the reaction using 
triethylamine (80%). Hence, the amine protection reaction using 
triethylamine was preferable. 
The protection step was followed by the thionation of 19 in the presence 
of diphosphorus pentasulfide (P4S10) to form 20. The combination of 
P4S10 and hexamethyldisiloxane (HMDO) could efficiently convert amide 
19 to carbothioamide 20. This thionation step has been previously 
achieved using Lawesson reagents (LR) in the Thomas group. However, a 
very low yield of product was obtained compared to thionation using 
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P4S10/HMDO. Additionally, the phosphorus-derived by-products (42 and 
43, Scheme 11) could be easily removed by simple aqueous workup, 
rather than by flash column chromatography, as required in LR reaction. 
Thus, thionation using P4S10/HMDO was preferable.  
Curphey reported that DCM, chloroform or benzene are the best solvents 
for thionations using P4S10/ HMDO as they gave better yields.
67 Thus, in 
this thionation step, 19 was stirred under reflux in chloroform together 
with HMDO and P4S10 for 3 hours. HMDO acts to increase the solubility of 
P4S10 in reaction solvents. Following this, the solution was cooled to 0 ˚C 
before 5.3 M potassium carbonate solution, water and acetone were 
added. The reason for adding water was to hydrolyse the expected by-
products, which are trimethylsilylated phosphates and thiophosphates 
(42 and 43, Scheme 11) to the corresponding acids. The resulting acids 
were water-soluble, and could be readily removed by water extraction. 
However, the reaction solvent used is immiscible with water. Hence, 
acetone was added to act as co-solvent in order to create a monophasic 
solution. As for 5.3 M potassium carbonate solution, it was used to buffer 
the reaction mixture, so that the strongly acidic conditions caused by 
hydrolysis of by-products could be avoided.  
The last step was the hydrolytic workup of the reaction solution to 
remove the reaction by-products and yield 20 as a clean oily yellow solid. 
The 1H NMR of 20 looked similar to 19. However, the formation 20 could 
be confirmed by IR and MS. The IR spectrum showed a strong absorption 
in the thioketones region (1169 cm-1). The reaction mechanism of the 
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thionation is shown in Scheme 10. Besides, the presence of the Boc 
methyl groups would also be a diagnostic indicator of 20. 
 
Scheme 10 Thionation reaction mechanism.  
As shown in Scheme 10, the P4S10 initially reacts with 19 to generate the 
thiocarbonyl intermediates, which yield 20 and species 41. 
Subsequently, 41 was reacted with HMDO to give soluble by-products, 
42 and 43 (Scheme 11). 
Curphey summarised the overall stoichiometry of the thionation reaction, 
which is shown in Scheme 11. This stoichiometry could be explained in 
two stages. The first stage involved the atoms exchange of the six 
bridging sulphur atoms with oxygen, leaving one atom of sulphur per 
phosphorus, giving structure 41. At the same time, 6 molecules of 
carbonyl 19 were converted into thiocarbonyl 20. At the second stage, 
five of the six P-O-P units in 41 reacted with five equivalent of HMDO in 
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the manner shown in Scheme 12. At the end of the reaction, one 
equivalent of diphosphate 43 was produced and the other two 
phosphorus atoms appeared as monophosphate 42.67  
 
Scheme 11 The overall stoichiometry of the thionation reaction.67 
 
Scheme 12 Reaction of HMDO. 
The removal of the BOC group using trifluoroacetic acid (TFA) in DCM 
was achieved after the thionation step, following by the amide coupling 
to 3-indoleacetic acid in the presence of HBTU and N,N-
diisopropylethylamine (DIPEA) in DMF. The deprotection step was 
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monitored by MS to assure the completion of the reaction was achieved. 
The reaction solvent was co-evaporated with chloroform in order to 
azeotropically remove TFA. The resulting brown residue was dried over 
phosphorus pentoxide under vacuum to remove water, to prevent a side 
reaction in amide coupling step.  
The reaction mechanism of the BOC deprotection is shown in Scheme 13. 
During the reaction, the tert-butyl cation was formed. Deprotonation of 
the cation form isobutylene, which is a gas. TFA was regenerated at the 
end of the reaction and CO2 gas was liberated. The crude product formed 
(36) was carried forward straight to the amide coupling step without the 
need for purification. 
 
Scheme 13 BOC deprotection reaction mechanism. 
Coupling agents play an important role in amide bond syntheses. One of 
the common amide coupling agents is HBTU. HBTU was first reported in 
its O-isomer form (37, Figure 17). Nevertheless, Carpino et al. disclosed 
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the structure of the active HBTU as the N-isomer (38, Figure 17) rather 
than O-isomer by X-ray crystallography.68   
 
Figure 17 Uronium and guanidinium isomers. 
In the amide coupling step, deprotected secondary amine 36 (Scheme 
13) was stirred in DMF with HBTU, DIPEA, and 3-indoleacetic acid to yield 
21. DMF was used as the reaction solvent as HBTU possessed good 
solubility in this solvent. Tertiary amine, DIPEA was chosen as the base 
in this amide coupling reaction due to its non-nucleophilic property. Also, 
DIPEA would not cause any degradation on HBTU. 
DIPEA acted to deprotonate 3-indoleacetic acid. After that, the coupling 
reagent, HBTU reacted with deprotonated acid to form active ester, 
which then reacted with secondary amine to form product 21. The by-
products formed were then removed by extraction and flash column 
chromatography to yield product 21. HOBT and DIPEA salts were 
removed by aqueous sodium hydrogen carbonate wash. The reaction 
mechanism is shown in Scheme 14. 
The yield obtained in this reaction was 31%, which is fairly low. This is 
because the coupling involves a secondary amine (piperidine) and hence 
was more difficult, due to steric hindrance.    
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This amide coupling reaction has been initially conducted on a small scale 
(3.0 g) experiment. It was observed that the scaled up experiment (6.0 
g) gave a higher yield (31%) comparing to the small scale experiment 
(3%).  
There has been a difficulty in purifying the crude product when the 
reaction was being scaled up. Co-elution of the product with the 
impurities was observed when silica chromatography was carried out. 
The solvent system used (ethyl acetate: acetone; 99:1) was previously 
established in the Thomas group. However, the crude product has been 
successfully purified by the use of the alternative solvent system (ethyl 
acetate).  
A small amount of the partially purified product has been used in the 
Hantzsch thiazole synthesis (Scheme 16). However, based on the MS 
obtained, an unknown impurity appeared to be the major peak compared 
to the desired product peak, which showed that the substituted 2-bromo-
acetophenone reacted more readily with the impurity than product 21. 
Therefore, purified product 21 has to be used in the next step. 
The reaction duration of this amide coupling step is important. An 
additional TLC spot (Rf = 0.50), which is an unknown impurity was 
observed when one of the reaction batches was left stirring under 
ambient temperature for 68 h rather than 23 h.    
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Scheme 14 Amide coupling reaction mechanism using HBTU. 
During the amide coupling step, a side reaction might take place when 
amine (36) reacted with HBTU to produce guanidinium by-product (39, 
Scheme 15). This might be one of the reasons why the yield of the 
product in this reaction step is low.   
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Scheme 15 Formation of guanidine side product. 
A series of indole analogues (22-35) were prepared via Hantzsch 
thiazole synthesis. This synthesis involved condensation of -haloketones 
with thioamide. This was achieved by dissolving 21 and substituted 2-
bromo-acetophenone in ethanol and stirred under reflux for 3-4 hours.  
Many attempts have been approached in purifying the crude product. A 
first attempt was to purify the crude product via gradient flash column 
chromatography on silica using DCM:MeOH (0-5% v/v) as eluent without 
any workup being performed. However, most of the products collected 
were impure, except for analogue 22. In some cases, fractions collected 
(24, 25, and 27), were recrystallised from hot methanol. 
After that, extraction was attempted before the flash chromatography 
using the same solvent system (DCM: MeOH), but no improvement was 
observed. Therefore, different solvent systems for the silica purification 
were explored, and the optimal solvent system, DCM: EtOAc (1: 1) was 
used to purify the rest of the analogues.  
The yields obtained for these analogues were between 23-78%. The low 
yield of some analogues was because the analogue has been purified 
twice (silica chromatography and recrystallisation) in a step. 
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In Hantzsch thiazole synthesis mechanism (Scheme 16), the first step is 
the nucleophilic displacement of bromide by thioamide to produce 
intermediate 44. The ketone is then attacked by the nitrogen nucleophile 
to form a cyclic hydroxyl intermediate 45. The removal of water in the 
last step furnishes the final products (22-35). 
 
Scheme 16 Hantzsch thiazole synthesis mechanism. 
Formations of analogues (22-35) were confirmed and these were fully 
characterised using MS and NMR techniques. The noticeable difference 
between all these analogues in 1H NMR spectra is the chemical shift of 
the aromatic protons in the region of 6.5-8.5 ppm. This is due to the 
effect of the functional groups (R’ and R’’) on the aromatic ring. The 
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protons are deshielded (higher frequency) or shielded (lower frequency) 
depending on the nature of the functional groups adjacent to them. The 
protons adjacent (a/a’, Table 3) to the electron-withdrawing groups will 
be deshielded, while the protons adjacent to the electron donating 
groups will be shielded. The chemical shifts of the aromatic protons are 
shown in Table 3.  
Table 3 NMR shifts of the aromatic protons influenced by different functional 
groups adjacent to them. 
 
Compounds H (ppm) 
  24 
a/a’ = 8.21 (Figure 18 (a)) 
b/b’ = 7.98 
  35 
a/a’ = 7.98 
b/b’ = 7.65 
  30 
a/a’ = 7.96 
b/b’ = 7.69 
  32 
a/a’ = 7.93 
b/b’ = 7.46 
59 
 
  28 
a/a’ = 7.90 
b/b’ = 7.21 
  31 
a/a’ = 7.88 
b/b’ = 7.24 
  34 
a/a’ = 7.78 
b/b’ = 7.37 
  26 
a/a’ = 7.73 
b/b’ = 7.53 
  23 
a/a’ = 7.41 
b/b’ = 7.87 
  25 
a/a’ = 7.20  
b/b’ = 7.75 
  27 
a/a’ = 6.93 (Figure 18 (b)) 
b/b’ = 7.79 
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(a) 
 
(b) 
Figure 18 1H NMR spectra of (a) 24 and (b) 27 in CDCl3 at 400 MHz, to show the 
effect of the substituted functional group to the chemical shifts (ppm). 
 
 
 
a/a’ 
(Shielded) b/b’ 
b/b’ 
a/a’ 
(Deshielded) 
 
 
27 
24 
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Another analogue that we attempted to synthesise was 36 (Figure 19). 
The MS obtained showed the presence of the product. However, the 
purification of the crude product was difficult. Poor separation of the 
product and the impurities was observed when different solvent systems 
were explored. Solvent systems, DCM:MeOH (94:6) and EtOAc:DCM 
(1:1) gave a good separation, but the fractions collected after silica 
chromatography was conducted were impure. Due to time limitations, a 
pure product was not isolated. 
 
Figure 19 Analogue that was failed to be purified. 
2.2 HPLC analysis of the analogues 
The purity of the analogues synthesised (22-35) were determined by 
using analytical reversed phase high performance liquid chromatography 
(RP-HPLC) on a C18 analytical column (Eclipse, XDS-C18, 5 µm, 4.6 x 
150 mm) at ambient temperature (Figure 20). Details of the analysis 
method can be found in section 4.2.2.  
Each of the analogues was dissolved in H2O: acetonitrile (1:1 v/v). The 
time frame set per analysis was 20 minutes and the average retention 
time for the 14 analogues was between 14-17 minutes. The eluted peak 
was collected so that the content could then be confirmed by MS. 
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The analytical data shows that the analogues have different purity levels, 
which is between 78-96% (Table 4). The purities of these analogues 
were obtained by calculating the percentage of main peak area in relation 
to total area of peaks under interest. 
The HPLC traces of some of the analogues (22, 24, 29, and 35) are 
shown in Figure 20. Analogues with purity more than 85% (22, 24, 27, 
33, and 34) are ideal for biological evaluation. However, the rest of the 
analogues require further purification prior to biological testing. 
Table 4 Purity data of the analogues. 
 
Analogue Structure Purity (%) 
22 
 
87 
23 
 
80 
24 
 
96 
25 
 
84 
26 
 
91 
63 
 
27 
 
95 
28 
 
83 
29 
 
78 
30 
 
81 
31 
 
80 
32 
 
81 
33 
 
85 
34 
 
92 
35 
 
79 
 
64 
 
         
                 (a)                  (b)                     (c)                 (d)                  
Figure 20 HPLC traces of the analogues, (a) 22; (b) 24; (c) 29; (d) 35. 
2.3 In silico evaluation 
In silico studies of the series of analogues was performed on the crystal 
structure of reduced drUGM (PDB code: 3HDQ)36 using GOLD69, 70. As 
mentioned earlier, UGM is catalytically active when it is in the reduced 
form. Also, reduced UGM has a threefold greater affinity for substrate 
than oxidized UGM (Km values of 66 µM versus 220 µM), hence, the 
reduced form of UGM was chosen.36 The crystal structure of drUGMred was 
used for the docking experiments initially.  
The crystal structure of the drUGM was obtained from the Protein Data 
Bank (PDB code: 3HDQ).36 The analogues were sketched using 
Chemdraw and saved in SMILES file in order to be converted into 3D 
form in SYBYL 8.0 (Tripos International, 1699 South Hanley Rd., St. 
Louis, Missouri, 63144, USA). Both structures of the inhibitors and 
protein molecule were prepared using SYBYL 8.0. During the process of 
creating a 3D structure, the molecule might have unfavourable bond 
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lengths, bond angles or torsion angles. Thus, the energy minimization 
step is important to generate molecules in their most stable 
conformation.  
The active site was defined with reference to the binding of UDP-Galp. 
The coordination set to define the centre of the active site was x = 
24.1245, y = -106.2594, and z = 73.4552. Then, the binding site radius 
was set to 10.0 Å, so that the binding site will be defined as all atoms 
that lie within the radius of the specified point. Default parameters were 
used for docking studies and 5 poses were requested for each analogue.   
During the docking process, GOLD scored docking solutions according to 
the fitness function set at the start. In this case, Goldscore is the fitness 
function employed as it is the default fitness function provided in GOLD. 
This fitness function predicts the ligand binding positions by taking into 
account factors such as hydrogen bonding energy, van der Waals energy, 
metal interaction and ligand torsion strain. The scores obtained from the 
result of docking illustrate how good the poses were. Therefore, the 
higher the score, the better the docking results. The poses with the 
highest score were chosen in order to evaluate their binding position in 
the active site. The Goldscore obtained (Table 4) from the docking of 14 
analogues were within the range of 79-86. By comparing to the 
Goldscore obtained for known inhibitor 17, which is 77.5, these 
analogues are predicted to bind well into the active site of drUGM. 
The images of the docking results were generated using PyMOL (The 
PyMOL Molecular Graphics System, Version 1.5.0.4 Schrödinger, LLC) in 
order to visualise the binding position.  
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Table 5 Docking result of the analogues. 
 
Ranking Inhibitors Structure Goldscores 
1 24 
 
85.2 
2 29 
 
85.0 
3 22 
 
84.4 
4 31 
 
84.1 
5 27 
 
83.9 
6 25 
 
83.7 
7 35 
 
83.2 
8 26 
 
82.0 
9 28 
 
81.7 
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10 33 
 
81.4 
11 30 
 
81.4 
12 23 
 
80.3 
13 34 
 
80.1 
14 32 
 
79.5 
15 17 
 
77.5 
 
Previously, Partha et al. has summarised the UGM active site into 3 
regions: the uridine binding region; the diphosphate binding region; and 
the sugar binding region.36 The uridine binding region consists of Phe176, 
Thr180, Trp184, Val199, and Tyr179. The diphosphate binding region 
was surrounded by Arg198, Arg305, and Tyr209. As for the sugar binding 
region, it was located close to isoalloxazine ring of FAD where it was 
surrounded by Pro84 and His109. 
The binding of UDP-Galp and previously reported inhibitor 17 to the 
drUGM binding site are shown in Figure 21 to demonstrate the 
similarities and differences to the binding of the analogues (22-35). 
68 
 
Obviously, these analogues have similar structural features to those seen 
for 17, except for the substituent of the thiazole ring.  
However, the binding modes of the majority of these analogues are 
entirely different to 17. The binding of the analogues, except 27 and 32, 
are 180˚ relative to 17, where the indole moiety of the analogues is 
pointing towards FAD isoalloxazine ring. This is because in this position, 
the indole moiety has more hydrogen interactions with the FAD 
isoalloxazine ring and Pro84, which may contribute to better inhibition 
comparing to other binding modes.   
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Figure 21 Chemdraw views of the binding of the substrate, (a) UDP-Galp and previously reported inhibitor, (b) 17 to the active site of 
drUGM.42 The hydrogen bond interactions to the amino acid residues are shown in green, and the stacking/hydrophobic interaction 
are shown in blue boxes. 
(a) (b) 
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Based on the docking results obtained, it can be seen that all these 
analogues bind in the same binding mode as UDP-Galp (as mentioned 
earlier in section 1.3.1) in the active site of drUGM, which is a folded U-
shaped conformation. The polar interactions between the inhibitors and 
the amino acid residues were generated as a dotted line, together with 
the bond distance. The strength of the hydrogen bonds is dependent on 
their bond distances. Jeffrey categorised hydrogen bonds with distances 
of 2.2-2.5 Å as strong, 2.5-3.2 Å as moderate, and 3.2-4.0 Å as weak.71 
The bond strength might be affected by the charge transfer interaction 
between the electron-deficient substituted aromatic ring and the 
electron-rich indole ring at two end of all the analogues. 
Analogue 24 appeared to have the highest score (Table 5) among the 
molecules. This is because it has more interactions to the amino acid 
residues compared to the others, including both hydrogen bonds and 
stacking/hydrophobic interactions (Figure 22). It can be seen that 
most of the interactions occurred around the indole moiety, which is 
located in the sugar binding region. The indole NH has hydrogen bond 
interactions with OH of Pro84; carbonyl, and NH of FAD. The piperidine 
moiety is located in the phosphate binding region. The carbonyl group 
that connects the indole ring and the piperidine moiety has hydrogen 
bond interactions with the side chain of Arg305. The nitro substituted 
aromatic moiety is located in the uridine binding region. The nitro group 
is shown to form a hydrogen bond interaction with NH of Pro123. The 
only stacking/ hydrophobic interaction can be found between the 
aromatic ring moiety and Phe176. Overall, analogue 24 has five 
hydrogen acceptors, one hydrogen donor and a  interaction.  
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Figure 22 Stereo image and corresponding Chemdraw view of the binding of 24 
to the active site of drUGM. The hydrogen bond interactions to the amino acid 
residues are shown in purple, together with bond distance, and the 
stackinginteraction is shown in box. 
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The rest of the analogues, except 27 and 32, exhibit a similar binding 
mode to that of 24 in the active site. However, unlike 24, the rest of the 
analogues do not show any hydrogen bond interaction between the 
aromatic substituents and the amino acid residues in the uridine binding 
region.  
The binding modes of the selected analogues (22, 26, and 29) are 
shown in Figure 23, Figure 25, and Figure 24 respectively. 22 does not 
seem to have any hydrophobic interaction with the residues in the uridine 
binding region. This is because the aromatic moiety that is located in the 
uridine binding region is facing away from the aromatic side chain of 
Phe176 (Figure 23). 
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Figure 23 Stereo image and corresponding Chemdraw view of the binding of 22 
to the active site of drUGM. The hydrogen bond interactions to the amino acid 
residues are shown in purple, together with bond distance. 
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Figure 24 Stereo image and corresponding Chemdraw view of the binding of 26 
to the active site of drUGM. The hydrogen bond interactions to the amino acid 
residues are shown in purple, together with bond distance, and the stacking 
interaction is shown in box. 
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Figure 25 Stereo image and corresponding Chemdraw view of the binding of 29 
to the active site of drUGM. The hydrogen bond interactions to the amino acid 
residues are shown in purple, together with bond distance. 
76 
 
The ligand binding was believed to be very flexible, and this could be 
explained by referring to the binding of 27 and 32 (Figure 26 and Figure 
27). Their binding is 180˚ relative to the rest of the analogues. This is 
because in this position, the indole moieties of both analogues have -
stacking/hydrophobic interaction with the aromatic ring of Phe176 and 
hydrogen bond interaction with carboxylic acid of Phe176, which may 
contribute to better binding affinity.  Besides, with this binding position, 
the aromatic ring substituent of 32 exhibits -stacking/hydrophobic 
interaction with the pyrrole ring of Pro84, which may increase the 
inhibition of the inhibitor. 
By comparing 27 and 32 to the previously synthesized inhibitor, 17 ((b)), 
their binding are similar. Their indole moieties are located in the uridine 
binding region, which is surrounded by Thr180, Phe175, and Phe176.  
However, the interactions of 27 and 32 to the binding residues are a bit 
similar compared to 17, except for the hydrophobic interaction of the 
indole rings to Tyr179 and hydrogen interaction of the carbonyl adjacent 
to the thiazole ring to Asn372. The indole NH of 27 forms a hydrogen 
bond to the carboxylic acid of Phe176. As for 32, the indole NH forms 
two hydrogen bonds to both Phe176 and Phe175. 
The thiazole N of 27 and 32 only forms a hydrogen bond to one of the 
NH, rather than both NH’s of Arg305. This is because the distance 
between the thiazole N and the two NH’s are 3.79 Å and 3.85 Å 
respectively.  Nevertheless, a very weak hydrogen bond might be formed 
with the NH further away. 
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The overall result shows that all these analogues are predicted to bind 
well in the active site. Moreover, most of them exhibit moderate 
hydrogen bond strength with the amino acid residues. Thus, they have 
the potential to act as good inhibitors of UGM. Inhibition assays will be 
carried out to further prove the potency of these analogues. 
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Figure 26 Stereo image and corresponding Chemdraw view of the binding of 27 
into the active site of drUGM. The hydrogen bond interactions to the amino acid 
residues are shown in purple, together with bond distance, and the stacking 
interaction is shown in box. 
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Figure 27 Stereo image and corresponding Chemdraw view of the binding of 32 
into the active site of drUGM. The hydrogen bond interactions to the amino acid 
residues are shown in purple, together with bond distance, and the stacking 
interaction is shown in box. 
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3 Conclusions and Future Work 
In conclusion, 14 indole-thiazole based potential inhibitors of UGM, with 
overall yields of 23-78% have been synthesized and successfully purified. 
The purity of all these inhibitors has been determined using HPLC and the 
results summarized that their purities are within the range of 78-96%, 
some of which are acceptable to be used for biological testing 
(compounds with purity greater than 85%). 
In silico studies of these compounds have been performed by docking 
them into the active site of the ligand-free drUGM crystal structure using 
the GOLD docking system. The Goldscore fitness function was employed 
to score the docking solutions, and the docking results obtained for these 
inhibitors are within the range of 79-86 cf. known inhibitor (17) 77.5. 
Subsequently, the interactions between the inhibitors and the UGM 
protein residues were evaluated. It can be concluded that these 
compounds show promising inhibitory activity towards drUGM.  
Future work will involve biological testing of these potential inhibitors 
using the isolated enzyme and whole cell assays to test the potency of 
these analogues. A FP assay can be adapted for the high-throughput 
screening of these analogues. In FP, a fluorescent probe (Figure 28) is 
used to monitor the inhibitory activity of the analogues. This can be done 
by measuring the emission of a fluorescent compound excited with plane-
polarized light. The variation of polarization depends upon whether the 
fluorescent probe is bound to UGM (high polarization, tumbling slowly) or 
displace by competitive inhibitor and released into solution (low 
polarization, tumbling rapidly).62 This assay has high sensitivity. 
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Dissociation constant (Kd) values of the analogues are measured. The 
smaller the Kd values, the higher the binding affinity of the analogues to 
UGM. 
 
Figure 28 Fluorescent probe used in FP assay.62 
Furthermore, the inhibition of these analogues can also be tested by 
conducting the HPLC assay, which involves the assessment of the 
catalytic activity of UGM. This can be achieved by monitoring the 
production of UDP-Galp from UDP-Galf. The percentage inhibition of 
these analogues is obtained. The percentage inhibition can be calculated 
using Equation 1. 
Equation 1 Calculation of the percentage inhibition. 
              
                    
(                    )   (                    )
 
In addition, further investigation of the inhibitory activity of these 
analogues will be achieved by performing docking experiments on UGM 
from different species, such as mtUGM, ecUGM, and kpUGM. 
Furthermore, some of the analogues with the purity lesser than 85% 
need to be further purified (using semi-preparative HPLC purification 
method) in order to be used for biological evaluation.  
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4 Experimental 
4.1 General  
All commercially available reagent grade solvents and reagents were 
purchased from Fischer Scientific®, Sigma Aldrich®, Alfa Aesar®, and 
Maybridge chemicals. 
All 1H NMR spectra were recorded on BrukerTM AV400, AV(III)400, or DPX 
400 spectrometers at 400 MHz, or AV(III)500 at 500 MHz and at ambient 
temperature. The chemical shifts (δ) given are in parts per million (ppm) 
and J values in Hertz (Hz). Multiplets are designated by the following 
notations: singlet (s), doublet (d), triplet (t), quartet (q), and multiplet 
(m). All spectra were recorded relative to residual solvent peaks. Spectra 
were recorded in solutions of deuterated chloroform (CDCl3, δsolv = 7.26) 
and deuterated methanol (CD3OD, δsolv = 3.31).
72  
All 13C NMR spectra were recorded on BrukerTM AV400, AV(III)400, or 
DPX 400 spectrometers at 100 MHz at ambient temperature, and the 
spectra were recorded relative to residual solvent peaks. Spectra were 
recorded in solutions of deuterated chloroform (CDCl3, δsolv = 77.1) and 
deuterated methanol (CD3OD, δsolv = 49.0).
72 All 19F NMR spectra were 
recorded on a BrukerTM AV400 spectrometer at 376 MHz under ambient 
temperature, and relative to residual solvent peaks using CFCl3 as a 
reference (CFCl3, δsolv = 0.00). All the NMR spectra were processed and 
analysed using TopSpin 3.0. The characterisation of all the compounds 
was based on DEPT 135, HMBC, and HMQC spectra.  
High resolution mass spectroscopy (HRMS) spectra were obtained on a 
BrukerTM microTOF, an orthogonal Time of Flight instrument with 
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electrospray ionisation (ESI, both positive and negative ion) sources as 
indicated. The values of mass to charge ratio (m/z), are given to four 
decimal places. The mass of the counter ions are H+ 1.0078, and Na+ 
22.9898. 
Infrared spectroscopy was recorded on a Thermo Scientific NICOLET 
IR200 FT-IR infrared spectrometer, with samples prepared as KBr discs.  
Thin layer chromatography was carried out on Merck Kieselgel 60 F254 
plates. Visualisation was by UV light and staining with phosphomolybdic 
acid (PMA) with heating.  
Flash column chromatography was performed using Merck Kieselgel silica 
gel 60 Å, 230-400 mesh, 40-63 µm,. 
A Stuart Scientific melting point apparatus (SMP3) was used to 
determine melting points, values are given in degrees Celsius (°C) and 
are uncorrected. 
An Agilent Technologies 1200 series HPLC with an Eclipse XDS-C18 5 µm 
column (4.6 x 150 mm) was used to run HPLC analyses at ambient 
temperature. All the HPLC grade solvents were purchased from Sigma 
Aldrich. Eluted HPLC peaks were detected by UV detector at 254 nm. 
Computational experiments were performed using different programs. 
SYBYL 8.0 (Tripos International, 1699 South Hanley Rd., St. Louis, 
Missouri, 63144, USA) was used to sketch and convert the inhibitor 
molecules into 3D form, and prepare the target UGM protein. GOLD69, 70 
was employed to perform the docking experiments. PyMOL (The PyMOL 
Molecular Graphics System, Version 1.5.0.4 Schrödinger, LLC) was used 
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to visualize the docking results, measure the interactions between the 
enzyme and substrates in 3D form, and generate the images of the 
docking results. The crystal structure of drUGM in complex with UDP-Galp 
was obtained from the RCSB Protein Data Bank (PDB code: 3HDQ), with 
the resolution of 2.36 Å. 
4.2 Procedures and Data 
4.2.1 Chemical synthesis 
4.2.1.1 Synthesis of tert-Butyl 4-carbamoyl piperidine-1-
carboxylate (19)73 
 
Isonipecotamide (5.15 g, 40.2 mmol) and triethylamine (11.2 ml, 39.4 
mmol) were dissolved in dichloromethane (200 mL). Di-tert-butyl 
dicarbonate (9.63 g, 44.6 mmol) in dichloromethane (20 mL) was added 
dropwise over 10 minutes and the resulting suspension was stirred at 
room temperature for 4 h forming a clear solution. The colourless 
solution was then washed with hydrochloric acid (1 M, 2 x 100 mL) and 
brine (2 x 100 mL). The organic layer was dried over magnesium 
sulphate (MgSO4), filtered and then concentrated in vacuo to yield a 
white solid (7.33 g, 32.1 mmol, 80%). Mp 156-158 °C (Lit. 154-156 
°C).74 IR vmax (KBr)/ cm
-1 3363 (N-H amine), 3190 (N-H amide), 2976 
(C-H alkanes), 1686 (C=O amide), 1433 (CH2); 
1H NMR δH (400 MHz, 
CDCl3) 1.46 (9H, s, 8-
tBu), 1.59-1.66 (2H, m, H3/5), 1.85 (2H, dd, J 12.0 
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Hz and 4.0 Hz, H3/5), 2.32 (1H, tt, J 12.0 Hz and 4.0 Hz, H4), 2.77 (2H, t, 
J 12.3 Hz, H2,6), 4.15 (2H, m, H2,6), 5.64 (2H, s, H15); 
13C NMR δC (100 
MHz, CDCl3) 28.5 (C10/11/12), 28.7 (C3/5), 42.7 (C4), 45.5 (C2/6), 79.7 (C9), 
154.7 (C7), 176.9 (C14) ; HRMS (ESI) required for C11H21N2O3
+ 229.1474 
(MH+) observed MH+ 229.1486. 
4.2.1.2 Synthesis of tert-butyl 4-carbamothioyl piperidine-1-
carboxylate (20)67 
 
tert-Butyl 4-carbamoyl piperidine-1-carboxylate (7.33 g, 32.1 mmol) was 
dissolved in chloroform (150 mL). Hexylmethylsiloxane (6.26 mL, 53.3 
mmol) and diphosphorus pentasulfide (1.87 g, 8.03 mmol) were added. 
The yellow resulting suspension was heated at reflux with stirring at 65 
°C for 3 h. The solution was then cooled to 0 °C, aqueous potassium 
carbonate solution (5.3 M, 10.4 mL), acetone (15.7 mL) and water (8.35 
mL) were added. The yellow solution was stirred at room temperature for 
18 h before being extracted with ethyl acetate (1 x 100 mL). The organic 
layer was washed with potassium carbonate solution (5.3 M, 2 x 50 mL), 
water (2 x 50 mL) and brine (2 x 50 mL). The organic layer was then 
dried over MgSO4, filtered and concentrated in vacuo to yield an oily 
yellow solid (5.86 g, 24.0 mmol, 75%). IR vmax (KBr solid)/ cm
-1  3346 
(NH2), 3177 (NH2), 2976 (C-H), 1671 (C=O), 1416 (CH3), 1169 (C=S); 
1H NMR δH (400 MHz, CDCl3) 1.47 (9H, s, 8-
tBu), 1.67-1.78 (2H, m, H5), 
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1.93 (2H, m, H3), 2.72 (4H, m, H6/2), 3.37 (1H, m, H4), 4.25 (2H, s, H15); 
13C NMR δC  (100 MHz, CDCl3) 28.4 (C10/11/12), 34.2 (C3/5), 45.9 (C2/6), 
51.2 (C4), 79.8 (C9), 159.5 (C7), 214.2 (C14); HRMS (ESI) required for 
C11H21N2O2S
+ 245.1245 (MH+) observed MH+ 245.1337. 
4.2.1.3 Synthesis of 12-(1H-indol-3-ylacetyl)piperidine-15-
carbothioamide (21)75, 76 
 
tert-Butyl 4-carbamothioylpiperidine-1-carboxylate (5.86 g, 24.0 mmol) 
was dissolved in dichloromethane (100 mL) and trifluoroacetic acid (37.5 
mL, 487 mmol) was added, the resulting suspension was stirred at room 
temperature for 3 h forming a solution. The yellow solution was co-
evaporated with chloroform and dried over phosphorus pentoxide under 
vacuum. HBTU (12.0 g, 31.7 mmol) and 3-indoleacetic acid (5.05 g, 28.8 
mmol) were added and dried under vacuum. DMF (30 mL) and DIPEA 
(15.3 mL, 88.0 mmol) were then added. The solution was stirred at room 
temperature for 23 h and then water (100 mL) was added and the 
solution was washed with ethyl acetate (2 x 100 mL), HCl (1 M, 2 x 70 
mL), sodium hydrogen carbonate (aq. sat., 2 x 70 mL) and brine (2 x 70 
mL). The organic layer was dried over MgSO4, filtered and concentrated 
in vacuo to give oily brown solid. Purification by flash column 
chromatography using ethyl acetate Rf 0.22 to yield a brown oil (2.22 g, 
7.37 mmol, 31%). Mp 105-107 °C. IR vmax (KBr)/ cm
-1  3298 (NH2), 1617 
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(C=O amide), 1456 (C=C aromatic), 774 (C-H aromatic); 1H NMR δH 
(400 MHz, CD3OD) 1.67-1.69 (4H, m, H14/16), 2.59 (1H, td, J 12.0 Hz and 
4.0 Hz, H17), 2.69-2.73 (1H, m, H15), 2.96-2.99 (1H, m, H13), 3.84 (2H, 
s, H10), 4.09 (1H, m, H13), 4.63 (1H, d, J 12.0 Hz, H17), 7.01-7.03 (1H, 
m, H2), 7.09 (2H, m, H5/6), 7.34 (1H, d, J 8.0 Hz, H4), 7.57 (1H, d, J 8.0 
Hz, H7). 
13C NMR δC  (100 MHz, CD3OD) 32.4 (C14), 32.7 (C16), 33.3 (C10), 
42.9 (C13), 47.3 (C17), 51.1 (C15), 109.3 (C3), 112.5 (C7), 119.5 (C4), 
120.1 (C5), 122.8 (C6), 124.2 (C2), 128.5 (C9), 138.1 (C8), 172.9 (C11), 
213.9 (C18); HRMS (ESI) required for C16H20N3OS
+ 302.1249 (MH+) 
observed MH+ 302.1265. 
4.2.1.4 General procedure of Hantzsch thiazole synthesis of 
indole analogues.77 
12-(1H-indol-3-ylacetyl)piperidine-15-carbothioamide (1.0 equiv.) and 
substituted 2-bromo-acetophenone (1.5 equiv.) were dissolved in ethanol 
(10 mL) and heated at reflux (90 °C) for 3-4 h. The ethanol was removed 
in vacuo to yield crude products. The crude products were purified by 
recrystallization or column chromatography. 
The following compounds were prepared in this manner. 
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4.2.1.4.1 Synthesis of 11-{15-1-piperidin-12-yl}-10-(1H-indol-
3-yl)-ethanone (22) 
 
22 was prepared from 12-(1H-indol-3-ylacetyl)piperidine-15-
carbothioamide (86 mg, 0.29 mmol) and 2-bromo-3’, 4’-
dichloroacetophenone (120 mg, 0.440 mmol). The crude product (purple 
foam) obtained was purified by flash column chromatography using 
dichloromethane: methanol (98: 2) Rf 0.38 as an oily brown solid (74 
mg, 0.16 mmol, 55%). IR vmax (KBr)/ cm
-1 3279 (N-H), 1626 (C=O 
amide), 1441 (C=C aromatics), 742 (C-H aromatics); 1H NMR δH (400 
MHz, CDCl3) 1.54-1.60 (1H, m, H17), 1.72-1.80 (2H, m, H13), 2.03 (1H, 
d, J 12.0 Hz, H17), 2.15 (1H, d, J 12.0 Hz, H13), 2.85 (1H, m, H16), 3.19 
(2H, m, H15,14), 3.90 (2H, s, H10), 4.05 (1H, d, J 12.0 Hz, H14), 4.73 (1H, 
d, J 12.0 Hz, H16), 7.07 (1H, d, J 4.0 Hz, H2), 7.14 (1H, m, H6), 7.21 (2H, 
m, H5), 7.36 (2H, m, H4,20), 7.46 (1H, d, J 8.0 Hz, H7), 7.66 (2H, dd, J 
4.0 Hz and 8.0 Hz, H27/28), 7.98 (1H, d, J 2.0 Hz, C24), 8.44 (1H, s, H1); 
13C NMR δC  (100 MHz, CDCl3) 31.6 (C10), 32.1 (C16), 32.5 (C14), 40.4 
(C15), 41.7 (C17), 46.0 (C13), 109.2 (C3), 111.3 (C20), 113.0 (C7), 118.7 
(C4), 119.7 (C5), 122.3 (C6), 122.4 (C2), 125.4 (C28), 127.1 (C9), 128.2 
(C24), 130.7 (C27), 131.8 (C23), 132.9 (C26), 134.4 (C25), 136.2 (C8), 
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152.5 (C21), 170.1 (C11), 174.4 (C18); HRMS (ESI) required for 
C24H22Cl2N3OS
+ 470.0782 (MH+) observed MH+ 470.0801. HRMS (ESI) 
required for C24H22Cl2N3OS
+ 472.0752 (MH+) observed MH+ 470.0771. 
4.2.1.4.2 Synthesis of 10-(1H-indol-3-yl)-11-(15-(21-
phenylthiazol-18-yl)piperidin-12-yl)ethanone (23) 
 
23 was prepared from 12-(1H-indol-3-ylacetyl)piperidine-15-
carbothioamide (100 mg, 0.330 mmol) and 2-bromoacetophenone (100 
mg, 0.500  mmol). The crude product (a purple oil) obtained was purified 
by flash column chromatography using dichloromethane: methanol (3%) 
Rf 0.30 as a yellow oil. Further purification by flash column 
chromatography using dichloromethane: ethyl acetate (1: 1) Rf 0.42 to 
give brown foam (54 mg, 0.14 mmol, 41%). Mp 78-80 °C; IR vmax (KBr)/ 
cm-1 3427 (N-H), 1625 (C=O amide), 1445 (C=C aromatics), 741 (C-H 
aromatics); 1H NMR δH (400 MHz, CDCl3) 1.55-1.59 (1H, m, H17), 1.73-
1.78 (1H, m, H13), 2.01 (1H, m, H17), 2.15 (1H, m, H13), 2.83 (1H, m, 
H16), 3.12-3.18 (1H, m, H14), 3.21-3.26 (1H, m, H15), 3.88 (2H, s, H10), 
4.01 (1H, d, J 13.7 Hz, H14), 4.73 (1H, d, J 13.4 Hz, H16), 7.04 (1H, m, 
H2), 7.13 (1H, m, H6), 7.20 (1H, m, H5), 7.30-7.34 (3H, m, H4,20,26), 7.34 
(1H, m, H4), 7.41 (2H, m, H25/27), 7.65 (1H, m, H7), 7.87 (2H, m, H24/28), 
8.77 (1H, s, H1); 
13C NMR δC  (100 MHz, CDCl3) 31.6 (C10), 32.2 (C13), 
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32.7 (C17), 40.5 (C15), 41.7 (C16), 46.0 (C14), 108.9 (qC), 111.5 (C4), 
111.8 (C20), 118.7 (C7), 119.5 (C6), 122.1 (C5), 122.7 (C2), 167.4 (C25/ 
27), 127.1 (qC), 128.1 (C26), 128.8 (C25/ 27), 134.4 ( qC), 136.3 (qC), 
155.0 (qC), 170.3 (qC), 173.9 (qC). HRMS (ESI) required for 
C24H24N3OS
+ 402.1562 (MH+) observed MH+ 402.1586. 
4.2.1.4.3 Synthesis of 10-(1H-indol-3-yl)-11-(15-(21-(26-
nitrophenyl)thiazol-18-yl)piperidin-12-yl)ethanone 
(24) 
 
24 Was prepared from 12-(1H-indol-3-ylacetyl)piperidine-15-
carbothioamide (103 mg, 0.340 mmol) and 2-bromo-4’-
nitroacetophenone (127 mg, 0.520  mmol). The crude product (a yellow 
residue) obtained was purified by flash column chromatography using 
dichloromethane: methanol (3% v/v) Rf 0.33 as a yellow oil. The yellow 
oil was purified further by recrystallization from methanol. The solid 
formed was filtered and washed with cold methanol to give yellow solid 
(36 mg, 0.26 mmol, 24%). IR vmax (KBr)/ cm
-1 3434 (N-H amine), 3174 
(N-H amide), 1603 (C=O amide), 1516 (NO2), 1459 (C=C 
aromatics),1343 (NO2), 737 (C-H aromatics);  
1H NMR δH (400 MHz, 
CDCl3) 1.54-1.60 (1H, m, H17), 1.74-1.79 (1H, m, H13), 2.04 (1H, d, J 
12.0 Hz, H17), 2.17 (1H, d, J 11.9 Hz, H13), 2.86 (1H, m, H16), 3.12-3.28 
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(2H, m, H14,15), 3.90 (2H, s, H10), 4.05 (1H, d, J 13.7 Hz, H14), 4.73 (1H, 
d, J 13.6 Hz, H16), 7.09 (1H, m, H2), 7.14 (1H, m, H6), 7.20 (1H, m, H5), 
7.35 (1H, d, J 8.0 Hz, H4), 7.54 (1H, s, H20), 7.65 (1H, d, J 7.9 Hz, H7), 
8.02 (2H, m, H24/28), 8.25 (2H, m, H25/27), 8.35 (1H, s, H1); 
13C NMR δC 
(100 MHz, CDCl3) 31.7 (C10), 32.2 (C13), 32.6 (C17), 40.6 (C15), 41.8 
(C16), 46.1 (C14), 109.4 (qC), 111.4 (C4), 115.4 (C20), 118.9 (C7), 119.8 
(C6), 122.4 (C5), 122.5 (C2), 124.3 (C25/27), 127.0 (C24/28), 136.3 (qC), 
140.4 (qC), 147.3 (qC), 152.7 (qC), 170.2 (qC), 174.9 (qC). HRMS (ESI) 
required for C24H23N4O3S
+ 447.1413 (MH+) observed MH+ 447.1447. 
4.2.1.4.4 Synthesis of 10-(1H-indol-3-yl)-11-(15-(21-(p-
tolyl)thiazol-18-yl)piperidin-12-yl)ethanone (25) 
 
25 Was prepared from 12-(1H-indol-3-ylacetyl)piperidine-15-
carbothioamide (102 mg, 0.340 mmol) and 2-bromo-4’-
methylacetophenone (109 mg, 0.550  mmol). The crude product 
obtained (a purple oil) obtained was purified by flash column 
chromatography using dichloromethane: methanol (3% v/v) Rf 0.21 as a 
yellow oil. The yellow oil was purified further by recrystallization from 
methanol. The solid formed was filtered and washed with cold methanol 
to give yellow solid (32 mg, 0.10 mmol, 23%). Mp 188-190 °C; IR vmax 
(KBr)/ cm-1 3434 (N-H amine), 3278 (N-H amide), 1628 (C=O amide), 
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1443 (C=C aromatics), 742 (C-H aromatics); 1H NMR δH (400 MHz, 
CDCl3) 1.56-1.61 (1H, m, H17), 1.76-1.81 (1H, m, H13), 2.03 (1H, d, J 
12.3 Hz, H17), 2.17 (1H, d, J 12.0 Hz, H13), 2.37 (3H, s, H29), 2.85 (1H, 
m, H16), 3.17 (1H, m, H14), 3.25 (1H, tt, J 3.9 and 11.2 Hz, H15), 3.89 
(2H, s, H10), 4.03 (1H, d, J 13.6 Hz, H14), 4.73 (1H, d, J 13.4 Hz, H16), 
7.07 (1H, m, H2), 7.14 (1H, m, H6), 7.18 (1H, m, H5), 7.20 (2H, m, 
H25/27), 7.27 (1H, s, H20), 7.35 (1H, d, J 8.0 Hz, H4), 7.64 (1H, d, J 8.0 
Hz, H7), 7.75 (2H, d, J 8.2 Hz, H24/28), 8.31 (1H, s, H1); 
13C NMR δC (100 
MHz, CDCl3) 21.4 (C29), 31.7 (C10), 32.3 (C13), 32.8 (C17), 40.6 (C15), 
41.8 (C16), 46.1 (C14), 109.5 (qC), 111.1 (C20), 111.4 (C4), 118.9 (C7), 
119.8 (C6), 122.4 (C5), 122.5 (C2), 126.4 (C24/28), 127.2 (qC), 129.5 
(C25/27), 155.2 (qC), 170.3 (qC). HRMS (ESI) required for C25H26N3OS
+ 
416.1718 (MH+) observed MH+ 416.1747. 
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4.2.1.4.5 Synthesis of 11-(15-(21-(26-bromophenyl)thiazol-18-
yl)piperidin-12-yl)-10-(1H-indol-3-yl)ethanone (26) 
 
26 Was prepared from 12-(1H-indol-3-ylacetyl)piperidine-15-
carbothioamide (106 mg, 0.350 mmol) and 2-4’-dibromoacetophenone 
(146 mg, 0.530  mmol). The crude product (a purple oil) obtained was 
purified by flash column chromatography using dichloromethane: ethyl 
acetate (1: 1) Rf 0.49 as a yellow solid (57 mg, 0.12 mmol, 34%). Mp 
191-193 °C; IR vmax (KBr)/ cm
-1 3431 (N-H amine), 3277 (N-H amide), 
1627 (C=O amide), 1441 (C=C aromatics), 745 (C-H aromatics); 1H NMR 
δH (400 MHz, CDCl3) 1.52-1.59 (1H, m, H17), 1.72-1.80 (1H, m, H13), 
2.05 (1H, m, H17), 2.17 (1H, m, H13), 2.85 (1H, m, H16), 3.16 (1H, m, 
H14), 3.26 (1H, m, H15), 3.89 (2H, s, H10), 4.03 (1H, d, J 13.6 Hz, H14), 
4.73 (1H, d, J 13.6 Hz, H16), 7.04 (1H, m, H2), 7.11 (1H, m, H6), 7.21 
(1H, m, H5), 7.34 (1H, s, H20), 7.36 (1H, m, H4), 7.53 (2H, m, H24/28), 
7.65 (1H, m, H7), 7.73 (2H, m, H25/27), 8.16 (1H, s, H1); 
13C NMR δC  (100 
MHz, CDCl3) 31.7 (C10), 32.3 (C13), 32.8 (C17), 41.0 (C15), 41.8 (C16), 
46.1 (C14), 109.6 (qC), 111.3 (C4), 112.3 (C20), 118.9 (C7), 119.9 (C6), 
122.3 (C5), 122.4 (C2), 127.2 (qC) 128.1 (C25/27), 132.0 (C24/28), 133.2 
(qC), 136.3 (qC),153.7 (qC), 170.1 (qC), 174.4 (qC). HRMS (ESI) 
required for C24H23BrN3OS
+ 480.0667 (MH+) observed MH+ 480.0695. 
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HRMS (ESI) required for C24H23BrN3OS
+ 482.0651 (MH+) observed MH+ 
482.0679. 
4.2.1.4.6 Synthesis of 10-(1H-indol-3-yl)-11-(15-(21-(26-
methoxyphenyl)thiazol-18-yl)piperidin-12-yl)ethan-
11-one (27) 
 
27 Was prepared from 12-(1H-indol-3-ylacetyl)piperidine-15-
carbothioamide (0.840 g, 2.79 mmol) and 2-bromo-4'-
methoxyacetophenone (0.960 g, 4.19 mmol). The crude product (a 
purple residue) obtained was purified by gradient flash column 
chromatography using dichloromethane: methanol (0-5% v/v) Rf 0.21 as 
an brown oil. The brown oil was purified further by recrystallization from 
methanol. The solid formed was filtered and washed with cold methanol 
to give yellow solid (0.33 g, 0.76 mmol, 27%). Mp 210-212 °C; IR vmax 
(KBr)/ cm-1 3268 (N-H),2951 (C-H alkane), 1628 (C=O amide), 1438 
(C=C aromatics), 1249 (COCH3), 746 (C-H aromatics); 
1H NMR δH (400 
MHz, CDCl3) 1.51-1.57 (1H, m, H17), 1.74-1.78 (1H, m, H13), 2.04 (1H, 
m, H17), 2.17 (1H, m, H13), 2.85 (1H, m, H16), 3.15 (1H, m, H14), 3.26 
(1H, m, H15), 3.84 (3H, s, H30), 3.89 (2H, s, H10), 4.03 (1H, d, J 13.6 Hz, 
H14), 4.73 (1H, d, J 13.4 Hz, H16), 6.93 (2H, m, H25/27), 7.08 (1H, m, H2), 
7.14 (1H, t, J 8.0 Hz, H6), 7.20 (2H, m, H5,20), 7.35 (1H, d, J 8.1 Hz, H4), 
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7.65 (1H, d, J 7.8 Hz, H7), 7.79 (2H, m, H24/28), 8.28 (1H, s, H1); 
13C 
NMR δC  (100 MHz, CDCl3) 31.6 (C10), 32.2 (C13), 32.7 (C17), 40.4 (C15), 
41.5 (C16), 46.1 (C14), 55.4 (C30), 109.5 (qC), 110.1 (C20), 111.4 (C4), 
114.2 (C25/27), 118.9 (C7), 119.8 (C6), 122.4 (C5), 122.5 (C2), 127.2 
(qC), 127.8 (C24/28), 136.3 (qC), 170.2 (qC). HRMS (ESI) required for 
C25H26N3O2S
+ 432.1667 (MH+) observed MH+ 432.1691. 
4.2.1.4.7 Synthesis of 11-(15-(21-(26-fluorophenyl)thiazol-18-
yl)piperidin-12-yl)-10-(1H-indol-3-yl)ethanone (28) 
 
28 Was prepared from 12-(1H-indol-3-ylacetyl)piperidine-15-
carbothioamide (113 mg, 0.380 mmol) and 2-bromo-4’-
fluoroacetophenone (122 mg, 0.570  mmol). The crude product (a purple 
oil) obtained was then dissolved in dichloromethane (100 mL) and 
washed with hydrochloric acid (1 M, 2 x 20 mL) and brine (2 x 20 mL). 
The organic layer was then dried over MgSO4, filtered and concentrated 
in vacuo to yield yellow oil. The yellow oil was purified by flash column 
chromatography using dichloromethane: ethyl acetate (1: 1) Rf 0.49 as a 
yellow oil (81 mg, 0.19 mmol, 51%). Mp 83-85 °C; IR vmax (KBr)/ cm
-1 
3430 (N-H), 1626 (C=O amide), 1456 (C=C aromatics), 744 (C-H 
aromatics); 1H NMR δH (400 MHz, CDCl3) 1.62-1.69 (1H, m, H17), 1.81-
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1.86 (1H, m, H13), 2.07 (1H, m, H17), 2.20 (1H, m, H13), 2.91 (1H, m, 
H16), 3.17 (1H, m, H14), 3.26 (1H, m, H15), 3.95 (2H, s, H10), 4.08 (1H, d, 
J 13.4 Hz, H14), 4.72 (1H, d, J 13.2 Hz, H16), 7.03 (1H, m, H2), 7.13-7.29 
(4H, m, H24/28, 6 ,5), 7.31 (1H, s, H20), 7.39 (1H, m, H4), 7.72 (1H, m, H7), 
7.90 (2H, m, H25/27), 8.94 (1H, s, H1); 
13C NMR δC  (100 MHz, CDCl3) 31.4 
(C10), 32.1 (C13), 32.6 (C17), 40.4 (C15), 41.7 (C16), 46.0 (C14), 108.8 
(qC), 111.4 (C4), 111.5 (C20), 115.6 (d, JC-C-F 21.1 Hz, C25/27), 118.6 (C7), 
119.5 (C6), 122.1 (C5), 122.7 (C2), 127.1 (qC), 128.1 (d, JC-C-F 8.0 Hz, 
C24/28), 130.8 (qC), 136.3 (qC), 153.9 (qC), 1612.7 (d, JC-F 245.8 Hz, 
C26), 170.3 (qC), 174.3 (qC). 
19F NMR (376 MHz, CDCl3) δ -113.6 (s, 1F, 
F29). HRMS (ESI) required for C24H23FN3OS
+ 420.1468 (MH+) observed 
MH+ 420.1494. 
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4.2.1.4.8 Synthesis of 11-(15-(21-(25-chlorophenyl)thiazol-18-
yl)piperidin-12-yl)-10-(1H-indol-3-yl)ethanone (29) 
 
29 Was prepared from 12-(1H-indol-3-ylacetyl)piperidine-15-
carbothioamide (128 mg, 0.430 mmol) and 2-bromo-3’-
chloroacetophenone (149 mg, 0.640  mmol). The crude product (a purple 
oil) obtained was then dissolved in dichloromethane (100 mL) and 
washed with hydrochloric acid (1 M, 2 x 20 mL) and brine (2 x 20 mL). 
The organic layer was then dried over MgSO4, filtered and concentrated 
in vacuo to yield brown oil. The brown oil was purified by flash column 
chromatography using dichloromethane: ethyl acetate (1: 1) Rf 0.53 as a 
yellow oil (100 mg, 0.230 mmol, 54%). 1H NMR δH (500 MHz, CDCl3) 
1.52-1.59 (1H, m, H17), 1.71-1.77 (1H, m, H13), 2.03 (1H, m, H17), 2.15 
(1H, d, m, H13), 2.85 (1H, m, H16), 3.15 (1H, m, H14), 3.24 (1H, tt, J 3.9 
and 11.3 Hz, H15), 3.89 (2H, s, H10), 4.03 (1H, d, J 13.5 Hz, H14), 4.73 
(1H, d, J 13.2 Hz, H16), 7.08 (1H, m, H2), 7.14 (1H, m, H6), 7.20 (1H, m, 
H5), 7.28-7.38 (4H, m, H28,27,4 ,20), 7.65 (1H, m, H7), 7.73 (1H, m, H26), 
7.87 (1H, m, H24), 8.36 (1H, s, H1); 
13C NMR δC (100 MHz, CDCl3) 31.6 
(C10), 32.1 (C13), 32.6 (C17), 40.4 (C15), 41.7 (C16), 46.0 (C14), 108.9 
(qC), 111.4 (C4), 112.9 (C20), 118.6 (C7), 119.5 (C6), 122.1 (C5), 122.6 
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(C2), 124.4 (C26), 126.5 (C24), 127.0 (qC), 128.0 (C28), 130.0 (C27), 
134.7 (qC), 136.2 (qC), 136.3 (qC), 153.4 (qC), 170.2 (qC), 174.3 (qC). 
HRMS (ESI) required for C24H23ClN3OS
+ 436.1172 (MH+) observed MH+ 
436.1199. HRMS (ESI) required for C24H22ClN3OS
+ 438.1142 (MH+) 
observed MH+ 438.1169. 
4.2.1.4.9 Synthesis of 26-(21-(15-(10-(1H-indol-3-
yl)acetyl)piperidin-12-yl)thiazol-18-yl)benzonitrile 
(30) 
 
30 Was prepared from 12-(1H-indol-3-ylacetyl)piperidine-15-
carbothioamide (133 mg, 0.440 mmol) and 2-bromo-4’-
cyanoacetophenone (149 mg, 0.660  mmol). The crude product (a purple 
oil) obtained was then dissolved in dichloromethane (100 mL) and 
washed with hydrochloric acid (1 M, 2 x 20 mL) and brine (2 x 20 mL). 
The organic layer was then dried over MgSO4, filtered and concentrated 
in vacuo to yield brown oil. The brown oil was purified by flash column 
chromatography using dichloromethane:ethyl acetate (1: 1) Rf 0.43 as a 
yellow solid (100 mg, 0.240 mmol, 53%). Mp 181-183 °C; IR vmax (KBr)/ 
cm-1 3419 (N-H amine), 3177 (N-H amide), 2224 (C≡N), 1605 (C=O 
amide), 1446 (C=C aromatics), 740 (C-H aromatics); 1H NMR δH (500 
MHz, CDCl3) 1.55-1.61 (1H, m, H17), 1.72-1.78 (1H, m, H13), 2.03 (1H, 
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d, J 11.9 Hz, H17), 2.16 (1H, d, J 11.9, H13), 2.85 (1H, m, H16), 3.17 (1H, 
m, H14), 3.23 (1H, m, H15), 3.90 (2H, s, H10), 4.05 (1H, d, J 14.0 Hz, 
H14), 4.73 (1H, d, J 13.6 Hz, H16), 7.11 (1H, m, H2), 7.14 (1H, m, H6), 
7.21 (1H, m, H5), 7.27 (1H, m, H4), 7.65 (1H, m, H7), 7.69 (2H, m, 
H24/28), 7.96 (2H, m, H25/27), 8.19 (1H, s, H1); 
13C NMR δC (100 MHz, 
CDCl3) 31.5 (C10), 32.3 (C13), 32.7 (C17), 40.6 (C15), 41.8 (C16), 46.1 
(C14), 109.6 (qC), 111.4 (C4), 114.7 (C20), 118.9 (C7), 119.9 (C6), 112.3 
(C2), 112.4 (C5), 126.9 (C25/27), 127.2 (qC), 132.8 (C24/28), 136.3 (qC), 
138.6 (qC), 153.1 (qC), 170.1 (qC). HRMS (ESI) required for 
C25H23N4OS
+ 427.1514 (MH+) observed MH+ 427.1537. 
4.2.1.4.10 Synthesis of 10-(1H-indol-3-yl)-11-(15-(21-(26-
(trifluoromethoxy)phenyl)thiazol-18-yl)piperidin-12-
yl)ethanone (31) 
 
31 Was prepared from 12-(1H-indol-3-ylacetyl)piperidine-15-
carbothioamide (130 mg, 0.430 mmol) and 2-bromo-1-[4-
(trifluoromethoxy)phenyl]ethan-1-one (183 mg, 0.650  mmol). The 
crude product (a purple oil) obtained was then dissolved in 
dichloromethane (100 mL) and washed with hydrochloric acid (1 M, 2 x 
20 mL) and brine (2 x 20 mL). The organic layer was then dried over 
MgSO4, filtered and concentrated in vacuo to yield brown oil. The brown 
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oil was purified by flash column chromatography using dichloromethane: 
ethyl acetate (1: 1) Rf 0.57 as a yellow oil (108 mg, 0.220 mmol, 51%). 
Mp 176-178 °C; IR vmax (KBr)/ cm
-1 3272 (N-H), 1626 (C=O amide), 
1445 (C=C aromatics), 1256 (COCF3), 1224 (C-F), 744 (C-H aromatics); 
1H NMR δH (400 MHz, CDCl3) 1.54-1.59 (1H, m, H17), 1.74-1.81 (1H, m, 
H13), 2.03 (1H, d, J 12.0 Hz, H17), 2.17 (1H, d, J 12.0 Hz, H13), 2.85 (1H, 
m, H16), 3.16 (1H, m, H14), 3.23 (1H, tt, J 3.9 and 11.2 Hz, H15), 3.89 
(2H, s, H10), 4.03 (1H, d, J 13.7 Hz, H14), 4.73 (1H, d, J 13.4 Hz, H16), 
7.05 (1H, m, H2), 7.14 (1H, m, H6), 7.20 (1H, m, H5), 7.24 (2H, m, 
H24/28), 7.33 (1H, s, H20), 7.36 (1H, m, H4), 7.64 (1H, m, H7), 7.88 (2H, 
m, H25/27), 8.29 (1H, s, H1); 
13C NMR δC  (100 MHz, CDCl3) 31.7 (C10), 
32.2 (C13), 32.7 (C17), 40.5 (C15), 41.0 (C16), 46.1 (C14), 109.5 (qC), 
111.4 (C4), 112.4 (C20), 118.9 (C7), 119.8 (C6), 121.3 (C25/27), 122.4 
(C5), 122.5 (C2), 127.2 (q, JC-F 277.1 Hz, C30), 127.9 (C24/28), 133.2 (qC), 
136.3 (qC), 170.2 (qC), 174.5 (qC). 19F NMR (376 MHz, CDCl3) δ -57.8 
(s, 3F, F31/32/33). HRMS (ESI) required for C25H23F3N3O2S
+ 486.1385 (MH+) 
observed MH+ 486.1409. 
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4.2.1.4.11 Synthesis of 11-(15-(21-([23,29'-biphenyl]-26-
yl)thiazol-18-yl)piperidin-12-yl)-10-(1H-indol-3-
yl)ethanone (32) 
 
32 Was prepared from 12-(1H-indol-3-ylacetyl)piperidine-15-
carbothioamide (123 mg, 0.410 mmol) and 2-bromo-4’-phenyl-
acetophenone (169 mg, 0.620  mmol). The crude product (a purple oil) 
obtained was then dissolved in dichloromethane (100 mL) and washed 
with hydrochloric acid (1 M, 2 x 20 mL) and brine (2 x 20 mL). The 
organic layer was then dried over MgSO4, filtered and concentrated in 
vacuo to yield brown oil. The brown oil was purified by flash column 
chromatography using dichloromethane: ethyl acetate (1: 1) Rf 0.56 as a 
yellow solid (92 mg, 0.19 mmol, 47%). Mp 171-172 °C; IR vmax (KBr)/ 
cm-1 3421 (N-H amine), 3204 (N-H amide), 3107 (C-H aromatics), 1621 
(C=O amide), 1447 (C=C aromatics), 749 (C-H aromatics); 1H NMR δH 
(500 MHz, CDCl3) 1.56-1.62 (1H, m, H17), 1.75-1.81 (1H, m, H13), 2.06 
(1H, m, H17), 2.19 (1H, d, J 12.0, H13), 2.87 (1H, m, H16), 3.16 (1H, m, 
H14), 3.26 (1H, tt, J 3.9 and 12.3 Hz H15), 3.90 (2H, s, H10), 4.05 (1H, d, 
J 13.7 Hz, H14), 4.74 (1H, d, J 13.4 Hz, H16), 7.08 (1H, m, H2), 7.14 (1H, 
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m, H6), 7.21 (1H, m, H5), 7.33-7.39 (3H, m, H4,20,32), 7.46 (2H, m, 
H31/33), 7.61-7.68 (5H, m, H7, 24/28, 30/34), 7.94 (2H, m, H25/27), 8.36 (1H, s, 
H1); 
13C NMR δC  (100 MHz, CDCl3) 31.7 (C10), 32.2 (C13), 32.8 (C17), 40.6 
(C15), 41.8 (C16), 46.1 (C14), 109.4 (qC), 111.4 (C4), 111.9 (C20), 118.9 
(C7), 119.8 (C6), 122.4 (C5), 122.5 (C2), 126.9 (C25/27),  127.1 (C30/34), 
127.5 (C32), 128.9 (C31/33), 133.4 (qC), 140.7 (qC), 140.9 (qC), 154.6 
(qC), 170.2 (qC), 174.2 (qC). 19F NMR (376 MHz, CDCl3) δ -62.5 (s, 3F, 
F30/31/32).HRMS (ESI) required for C30H28N3OS
+ 478.1875 (MH+) observed 
MH+ 478.1896. 
4.2.1.4.12 Synthesis of 11-(15-(21-(25-fluorophenyl)thiazol-18-
yl)piperidin-12-yl)-10-(1H-indol-3-yl)ethanone (33) 
 
33 Was prepared from 12-(1H-indol-3-ylacetyl)piperidine-15-
carbothioamide (136 mg, 0.410 mmol) and 2-bromo-1-(3-
fluorophenyl)ethan-1-one (147 mg, 0.0680  mmol). The crude product (a 
purple oil) obtained was then dissolved in dichloromethane (100 mL) and 
washed with hydrochloric acid (1 M, 2 x 20 mL) and brine (2 x 20 mL). 
The organic layer was then dried over MgSO4, filtered and concentrated 
in vacuo to yield brown oil. The brown oil was purified by flash column 
chromatography using dichloromethane: ethyl acetate (1: 1) Rf 0.51 as a 
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yellow oil (97 mg, 0.23 mmol, 56%). 1H NMR δH (500 MHz, CDCl3) 1.52-
1.58 (1H, m, H17), 1.71-1.77 (1H, m, H13), 2.03 (1H, d, J 12.3 Hz, H17), 
2.15 (1H, d, J 12.3 Hz, H13), 2.85 (1H, m, H16), 3.15 (1H, m, H14), 3.24 
(1H, tt, J 4.0 and 12.1 Hz, H15), 3.89 (2H, s, H10), 4.03 (1H, d, J 12.4 Hz, 
H14), 4.73 (1H, d, J 12.3 Hz, H16), 7.01 (1H, m, H27), 7.07 (1H, m, H2), 
7.14 (1H, m, H6), 7.20 (1H, m, H5), 7.33-7.39 (3H, m, H28, 4 , 20), 7.58 
(1H, m, H26), 7.62 (1H, m, H24), 7.65 (1H, m, H7), 8.35 (1H, s, H1); 
13C 
NMR δC  (100 MHz, CDCl3) 31.7 (C10), 32.2 (C13), 32.7 (C17), 40.6 (C15), 
41.0 (C16), 46.0 (C14), 111.4 (C4), 112.8 (C20), 113.5 (d, JC-C-F 22.5 Hz, 
C24), 114.9 (d, JC-C-F 21.1 Hz, C26), 118.7 (C7), 119.6 (C6), 121.9 (d, JC-C-C-
F 3.0 Hz, C27), 122.2 (C5), 122.6 (C2), 127.1 (qC), 130.4 (C28), 136.3 
(qC), 136.7 (qC), 153.7 (qC), 163.2 (d, JC-F 243.7 Hz, C25), 170.3 (qC), 
174.3 (qC). 19F NMR (376 MHz, CDCl3) δ -112.9 (s, F29). HRMS (ESI) 
required for C24H23FN3OS
+ 420.1468 (MH+) observed MH+ 420.1489. 
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4.2.1.4.13 Synthesis of 11-(15-(21-(26-chlorophenyl)thiazol-18-
yl)piperidin-12-yl)-10-(1H-indol-3-yl)ethanone (34) 
 
34 Was prepared from 12-(1H-indol-3-ylacetyl)piperidine-15-
carbothioamide (125 mg, 0.420 mmol) and 2-bromo-4’-
cyanoacetophenone (145 mg, 0.620  mmol). The crude product (a purple 
oil) obtained was then dissolved in dichloromethane (100 mL) and 
washed with hydrochloric acid (1 M, 2 x 20 mL) and brine (2 x 20 mL). 
The organic layer was then dried over MgSO4, filtered and concentrated 
in vacuo to yield brown oil. The brown oil was purified by flash column 
chromatography using dichloromethane: ethyl acetate (1: 1) Rf 0.61 as a 
yellow solid (89 mg, 0.21 mmol, 49%). Mp 192-194 °C; IR vmax (KBr)/ 
cm-1 3278 (N-H), 1627 (C=O amide), 1442 (C=C aromatics), 745 (C-H 
aromatics); 1H NMR δH (400 MHz, CDCl3) 1.52-1.58 (1H, m, H17), 1.74-
1.79 (1H, m, H13), 2.03 (1H, m, H17), 2.15 (1H, m, H13), 2.85 (1H, m, 
H16), 3.15 (1H, m, H14), 3.23 (1H, m, H15), 3.89 (2H, s, H10), 4.03 (1H, d, 
J 13.5 Hz, H14), 4.72 (1H, d, J 13.4 Hz, H16), 7.04 (1H, m, H2), 7.14 (1H, 
m, H6), 7.20 (1H, m, H5), 7.32 (1H, s, H20), 7.34 (1H, m, H4), 7.37 (2H, 
m, H24/28), 7.65 (1H, m, H7), 7.78 (2H, m, H25/27), 8.29 (1H, s, H1); 
13C 
NMR δC  (100 MHz, CDCl3) 31.7 (C10), 32.2 (C13), 32.7 (C17), 40.6 (C15), 
41.0 (C16), 46.0 (C14), 109.4 (qC), 111.4 (C4), 112.2 (C20), 118.9 (C7), 
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119.8 (C6), 122.4 (C5), 122.5 (C2), 127.7 (C25/27), 129.0 (C24/28), 133.0 
(qC), 134.0 (qC),136.3 (qC), 153.8 (qC), 170.2 (qC), 174.3 (qC). HRMS 
(ESI) required for C24H23ClN3OS
+ 436.1172 (MH+) observed MH+ 
436.1193. HRMS (ESI) required for C24H23ClN3OS
+ 438.1142 (MH+) 
observed MH+ 438.1163. 
4.2.1.4.14 Synthesis of 10-(1H-indol-3-yl)-11-(15-(21-(26-
(trifluoromethyl)phenyl)thiazol-18-yl)piperidin-12-
yl)ethanone (35) 
 
35 Was prepared from 12-(1H-indol-3-ylacetyl)piperidine-15-
carbothioamide (133 mg, 0.440 mmol) and 2-bromo-4’-phenyl-
acetophenone (178 mg, 0.660  mmol). The crude product (a purple oil) 
obtained was then dissolved in dichloromethane (100 mL) and washed 
with hydrochloric acid (1 M, 2 x 20 mL) and brine (2 x 20 mL). The 
organic layer was then dried over MgSO4, filtered and concentrated in 
vacuo to yield brown oil. The brown oil was purified by flash column 
chromatography using dichloromethane: ethyl acetate (1: 1) Rf 0.56 as a 
yellow solid (120 mg, 0.260 mmol, 58%). Mp 167-169 °C; IR vmax (KBr)/ 
cm-1 3281 (N-H), 1627 (C=O amide), 1445 (C=C aromatics), 1327 (C-F), 
745 (C-H aromatics); 1H NMR δH (400 MHz, CDCl3) 1.54-1.61 (1H, m, 
H17), 1.74-1.79 (1H, m, H13), 2.04 (1H, d, J 11.9 Hz, H17), 2.17 (1H, d, J 
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12.3 Hz, H13), 2.86 (1H, m, H16), 3.16 (1H, m, H14), 3.24 (1H, tt, J 3.8 
and 11.3 Hz, H15), 3.90 (2H, s, H10), 4.03 (1H, d, J 13.6 Hz, H14), 4.73 
(1H, d, J 13.3 Hz, H16), 7.03 (1H, s, H2), 7.14 (1H, m, H6), 7.20 (1H, m, 
H5), 7.35 (1H, m, H4), 7.24 (1H, m, H20), 7.61 (1H, m, H7), 7.65 (2H, d, 
J 8.0 Hz, H24/28), 7.98 (2H, d, J 8.0 Hz, H25/27), 8.40 (1H, s, H1); 
13C NMR 
δC (100 MHz, CDCl3) 31.7 (C10), 32.2 (C13), 32.8 (C17), 40.6 (C15), 41.0 
(C16), 46.1 (C14), 109.4 (qC), 111.4 (C4), 113.7 (C20), 118.8 (C7), 119.8 
(C6), 122.4 (C5), 122.5 (C2), 125.8 (m, JC-C-C-F 5.8 Hz , C25/27),  126.6 
(C24/28), 127.2 (qC), 136.3 (qC), 137.7 (qC), 153.6 (qC), 170.2 (qC), 
174.5 (qC). 19F NMR (376 MHz, CDCl3) δ -62.5 (s, 3F, F30/31/32). HRMS 
(ESI) required for C25H23FN3OS
+ 470.1436 (MH+) observed MH+ 
470.1457. 
4.2.2 HPLC purity analysis of the inhibitors 
Chromatographic conditions: 
An Eclipse XDS-C18 5 µm column (4.60 x 150 mm) was used at ambient 
temperature. The mobile phase was composed of acetonitrile (50% v/v) 
and methanol (50% v/v). Its flow rate was 1 mL/minute with a maximum 
pressure limit of 350 bar. The stop time was set at 20 minutes, injection 
volume of 20 µL, and signal detection at 254 nm. The experiments were 
conducted at ambient temperature. 
Apparatus used:  
Sonomatic Langford Ultrasonics was used to sonicate the sample 
solutions. 1 mL BD PlastipakTM syringe, Class A/B glasswares, and Fischer 
MH-124 balance were used to prepare all the sample solutions and 
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mobile phase. The analysis was carried out using Agilent Technologies 
1200 Infinity series G1322A Degasser (Serial no.: JP73071492), G1311A 
Quat Pump (Serial no.: DE62971498), G1314B VDW (Serial no.: 
DE71365292), G164C Analyt FC (Serial no.: DE63056626), and G1328B 
Man. Inj. (Serial no.: DE60561146). 
Sample preparation:  
The sample solution (1 mg/mL) was prepared by dissolving 1 mg of each 
compound using 1 mL of mobile phase in a sample vial. Sample was 
sonicated to ensure that the compounds were completely dissolved in the 
mobile phase. The solution contained test analogues were then filtered 
using a 0.45 µm syringe filter fitted to a 1 mL syringe.  
4.2.3 In silico studies 
The crystal structure of drUGM in complex with UDP-Galp (PDB code: 
3HDQ)36 was used for docking studies using GOLD. The structures of the 
inhibitors were sketched and minimized using SYBYL 8.0. The protein 
molecule was energy minimized using SYBYL 8.0, UDP-Galp was 
removed, and hydrogen atoms were added. The active site was defined 
using UDP-Galp as the reference molecule. The coordination set to define 
the centre of active site was x = 24.1245, y = -106.2594, and z = 
73.4552. The binding site radius was set to 10.0 Å. All default 
parameters were used for docking studies and 5 poses were requested 
for each molecule. Best fit was determined based upon the Goldscore 
fitness function. The highest score among the 5 poses of each molecule 
was chosen in order to observe the potential interactions to the protein 
residues and the binding conformation.  
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